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Opioids selective for the G protein-coupled mu opioid receptor (MOR) produce potent
analgesia and euphoria. Heroin, a synthetic opioid, is considered one of the most addictive
substances, and the recent exponential rise in opioid addiction and overdose deaths
has made treatment development a national public health priority. Existing medications
(methadone, buprenorphine, and naltrexone), when combined with psychosocial therapies,
have proven efﬁcacy in reducing aspects of opioid addiction. Unfortunately, these medica-
tions have critical limitations including those associated with opioid agonist therapies (e.g.,
sustained physiological dependence and opioid withdrawal leading to high relapse rates
upon discontinuation), non-adherence to daily dosing, and non-renewal of monthly injection
with extended-release naltrexone. Furthermore, current medications fail to ameliorate
key aspects of addiction such as powerful conditioned associations that trigger relapse
(e.g., cues, stress, the drug itself). Thus, there is a need for developing novel treatments
that target neural processes corrupted with chronic opioid use. This requires a basic
understanding of molecular and cellular mechanisms underlying effects of opioids on
synaptic transmission and plasticity within reward-related neural circuits. The focus of
this review is to discuss how crosstalk between MOR-associated G protein signaling and
glutamatergic neurotransmission leads to immediate and long-term effects on emotional
states (e.g., euphoria, depression) and motivated behavior (e.g., drug-seeking, relapse).
Our goal is to integrate ﬁndings on how opioids modulate synaptic release of glutamate
and postsynaptic transmission via α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
and N -methyl-D-aspartate receptors in the nucleus accumbens and ventral tegmental area
with the clinical (neurobehavioral) progression of opioid dependence, as well as to identify
gaps in knowledge that can be addressed in future studies.
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INTRODUCTION
Opioids comprise a class of endogenous, naturally occurring
and synthetic compounds that bind to and activate one of three
known opioid receptors: mu, delta, and kappa (MOR, DOR,
KOR, respectively). All opioids possess analgesic properties, which
humans have taken advantage of for thousands of years. They
also have profound effects on physiology and mood that depend
on the speciﬁc opioid receptor and site of action in the brain.
Opiates, a subclass of opioids that are natural derivatives of
the opium plant, papaver somniferum, include morphine and
codeine, which are the two major metabolites of heroin. These
compounds primarily activate MORs to produce euphoria that
can motivate repeated self-administration, produce tolerance,
dependence, and ultimately opioid addiction. One percent of all
Americans meet criteria for having an opioid use disorder (OUD);
heroin use has doubled since 2007, and 2% of all Americans
age 12 and older report misuse of a prescription opioid anal-
gesic within the past 30 days (NSDUH, 2013). In 2008, there
were 15,000 accidental overdose deaths related to prescription opi-
oid use alone (Center for Disease Control) and opioid analgesics
are second only to marijuana as the ﬁrst illicit drug reported
taken by 1.9 million youth and older adult Americans (NSDUH,
2013). The partial MOR agonist buprenorphine combined with
the diversion-preventing opioid receptor antagonist naloxone has
been partially successful in engaging youth and adults with OUD
into abstinence-focused treatment (Fudala et al., 2003; Mattick
et al., 2008; Woody et al., 2008; Weiss et al., 2011). However, con-
trolled data on longer-term outcomes is lacking and patients
taking agonist therapies (e.g. the long-lasting, full MOR ago-
nist methadone and buprenorphine) have high rates of relapse
(>75%) upon medication withdrawal (Woody et al., 2008; Weiss
et al., 2011).
In fact, the treatment course of OUD is primarily chal-
lenged by the experience of the opioid withdrawal syndrome
(OWS), which is characterized by both a typical physical syn-
drome occurring acutely (24–48 h post-withdrawal) and also by
an affective/cognitive syndrome of dysphoria, anxiety, irritability,
and preoccupation with cravings to use opioids (Kreek and Koob,
1998). These affective withdrawal symptoms occur acutely, but
they frequently have a protracted course in humans (Dole et al.,
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1966; Martin and Jasinski, 1969; see Table 1). Acute and protracted
OWS is observed in controlled studies and in clinical practice to
precipitate resumed opioid use; this is not only true for those ﬁrst
entering treatment and inexperienced in recovery practices but
also true for those in longer-term recovery on agonist therapy who
experience OWS during attempts to discontinue agonist therapy
(Magura and Rosenblum, 2001; Woody et al., 2008; Weiss et al.,
2011). Therefore, there is a great need to develop newer, medical
therapies that are not pharmacologically based on opioids them-
selves to assist peoplewithOUD in toleratingOWSwithout relapse
to opioid use.
The affective/cognitive components of OWS may be the
most important target for drug development, since non-opioid
medications (e.g., adrenergic antagonists, anti-emetics, sedative-
hypnotics) already exist and are widely applied to treat aspects
of the physical syndrome. Research in rats demonstrates that
naloxone-induced heightened acoustic startle, a pre-clinical proxy
for anxiety sensitivity, persists up to 80 days following a single
administration of morphine, whereas naloxone-induced condi-
tioned place aversion is not seen after 20 days (Rothwell et al.,
2012), suggesting that anxiety may be one of the most persis-
tent protracted symptoms of the OWS. In addition, one clinical
study in prescription opioid-dependent individuals suggests that
when patients are blinded to buprenorphine taper schedules, their
success rates in moving through opioid withdrawal to achieve sus-
tained opioid abstinence may be improved (Sigmon et al., 2013).
This could reﬂect a signiﬁcant component of anticipatory anxi-
ety about OWS under conditions where individuals are aware of
forced reduction.
In order to most successfully treat affective/cognitive com-
ponents of the OWS, it is imperative to understand how the
normal brain processes rewarding and aversive stimuli to mod-
ulate behavior, and how opioids subsequently act to change
behavior. Excitatory glutamatergic neurotransmission provides a
basis for communication between neurons that enables behavior.
Table 1 | Symptoms of unmedicated abstinence in heroin-dependent
men*.
Days of abstinence
Day 3 Day 10 Day 30
• Severe anxiety • Moderate anxiety • Mild anxiety
• Moderate depression • Subclinical depression • Mild depressive
symptoms
• Highest craving • Moderate craving • Milder craving





*Based on results of two studies reported by Li et al. (2009) and Shi et al. (2009);
anxiety measured by the Hamilton Anxiety Scale (HAM-A), depression by the
Beck Depression Inventory (BDI).
Depending on the neural circuits activated, behavior can refer
to anticipated stimuli, emotional response, learning (stimulus-
response), or action – all of which become dysfunctional with
addiction. The goal of this review is to present and syn-
thesize the current state of knowledge on how activation of
MORs modulates glutamatergic neurotransmission through α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)
and N-methyl-D-aspartate (NMDA) receptors. We will focus on
MOR–glutamate interactions within the mesolimbic dopamine
system, a key neural substrate for the affective consequences
of acute and chronic opioids. The basic pharmacology, neu-
roanatomical localization, and physiology of MORs have beenwell
studied in in vitro systems, animal models, and clinical research,
and there are numerous comprehensive reviews describing these
ﬁndings (Law et al., 2000; Williams et al., 2001, 2013; Shalev et al.,
2002; Waldhoer et al., 2004; Bailey and Connor, 2005; Pasternak,
2012).
MOR DISTRIBUTION AND ACTIONS
Mu opioid receptors are expressed throughout the brain. Several
comprehensive studies have been published in which MOR bind-
ing sites are mapped (Mansour et al., 1988, 1994; Le Merrer et al.,
2009). MORs are generally perisynaptic: they can be localized
postsynaptically on dendrites and cell bodies where they regulate
neuronal excitability and transduce receptor activation to down-
stream signal transductionpathways, and they can also be localized
presynaptically on axon terminals where they inhibit neurotrans-
mitter release via activation of K+ conductance and/or inhibition
of Ca2+ conductance (Williams et al., 2001). The cellular and neu-
roanatomical distribution of MORs is critical for understanding
the neural circuits involved in the initiation of opiate action and
subsequent plasticity with chronic drug use.
In the context of opiate dependence and withdrawal, several
key neuroanatomical substrates have been identiﬁed, in par-
ticular the reciprocal connections within the limbic subcircuit
of corticostriatal circuitry: GABAergic neurons of the nucleus
accumbens (NAc), dopaminergic neurons of the ventral tegmental
area (VTA), and glutamatergic neurons of the prefrontal cor-
tex (PFC). Importantly, these regions contribute to acute opiate
reward, dependence, tolerance, somatic and affective signs of
withdrawal, and relapse (Wise, 1989; Stinus et al., 1990; Harris
and Aston-Jones, 1994; Bonci and Williams, 1997; LaLumiere and
Kalivas, 2008; Chartoff et al., 2009; Shen and Kalivas, 2013). Rats
will self-administer opiates directly into the VTA (Bozarth and
Wise, 1983; Devine and Wise, 1994), which contains dopamin-
ergic cell bodies, and into the ventral striatum NAc (Olds, 1982),
which receives dopaminergic input from theVTA.Acutemorphine
increases dopamine release in the NAc (Di Chiara and Imperato,
1988b; Johnson and North, 1992) by inhibiting GABAergic neu-
rons in the VTA and rostromedial tegmental nucleus (RMTg) that
synapse on dopaminergic neurons (Tepper et al., 1995; Jalabert
et al., 2011). Morphine dependence – characterized by physical
and psychological withdrawal signs – is mediated by several brain
regions, with the locus coeruleus and periaqueductal gray (PAG)
regionmost sensitive to naloxone-precipitated somaticwithdrawal
symptoms (Koob et al., 1992). The mesolimbic system is also
important for morphine dependence, with a key role in affective
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signs of withdrawal: microinjections of naloxone into the NAc
causes conditioned place aversions (Koob et al., 1992), and admin-
istration of a dopamineD2-like, but not aD1-like, receptor agonist
directly into the NAc attenuates somatic withdrawal signs (Harris
and Aston-Jones, 1994). Also, dopamine release is decreased in
the NAc during morphine withdrawal (Rossetti et al., 1992; Diana
et al., 1995; Bonci and Williams, 1997), suggesting that the NAc
may mediate certain aspects of morphine dependence. Other key
brain regions important for opiate dependence include, but are
not limited to, the amygdala, hippocampus, and bed nucleus of
the stria terminalis (Mansour et al., 1995b; Gracy et al., 1997).
MOR ACTIVATION AND INTRACELLULAR SIGNALING
The physiological effects of morphine are absent in mice lacking
MORs (Matthes et al., 1996; Le Merrer et al., 2009), providing
strong support for the idea that MORs are necessary for the
clinically relevant effects of opiates. MORsbelong to theGprotein-
coupled receptor (GPCR) superfamily of seven transmembrane
receptors and the rhodopsin receptor subfamily and are linked
to pertussis toxin-sensitive inhibitory heterotrimeric guanosine
triphosphate-binding proteins (Gαi/Gαo). Overall, MORs, DORs,
and KORs are approximately 60% identical to each other (Chen
et al., 1993).
Upon MOR activation, G protein α and βγ subunits interact
with downstream effector systems to inhibit adenylyl cyclase and
voltage-gated Ca2+ channels and to stimulate G protein-activated
inwardly rectifying K+ channels (GIRKs) and phospholipase
Cβ (Childers, 1991; Waldhoer et al., 2004; Williams et al., 2013;
see Figures 1 and 2, Naïve condition, for depiction of MOR-
dependent signaling). In the presence of chronic morphine, a
compensatory increase in adenylyl cyclase activity occurs and
cAMP levels return to normal (see Figures 1 and 2, GABAer-
gic neurons in Naïve, Acute, and Chronic conditions). When
morphine is discontinued or withdrawal is pharmacologically pre-
cipitated, cAMP levels dramatically increase (see Figures 1 and 2,
GABAergic neurons in Withdrawal condition; Nestler and Agha-
janian, 1997; Williams et al., 2001). This phenomenon of early
inhibition and late positive regulation of adenylyl cyclase by mor-
phine has been demonstrated in several morphine-receptive brain
regions (Duman et al., 1988; Nestler andTallman,1988; Terwilliger
et al., 1991; Van Vliet et al., 1991; Self et al., 1995; Shaw-Lutchman
et al., 2002). Upregulation of the cAMP pathway observed during
morphine withdrawal activates cAMP-dependent protein kinase
A (PKA; Chartoff et al., 2003a,b, 2006). Interestingly, it has been
reported that the increase in adenylyl cyclase activity may itself
result in a decrease in transcript levels of particular cyclases in the
striatum (Spijker et al., 2004).
Protein kinase A phosphorylates and activates numerous sub-
strates, including the transcription factor cAMP response element
binding protein (CREB) and the AMPA receptor (AMPAR)
subunit GluR1 (Figure 1, Withdrawal condition; Figure 3; Kon-
radi et al., 1994; Chartoff et al., 2003b, 2006; Mangiavacchi and
Wolf, 2004). Optimal PKA-mediated increases in CREB and
GluR1 signaling requires NMDA receptor (NMDAR) activation
(Konradi et al., 1996; Wolf, 2010), providing early evidence
for crosstalk between MORs and glutamatergic transmission.
It is through these actions that morphine and heroin may
ultimately modulate fast excitatory transmission via AMPAR and
NMDAR.
GLUTAMATERGIC NEUROTRANSMISSION
The classic view of glutamate action comprises presynaptic release
of glutamate, binding to postsynaptic ionotropic receptors, and
clearance of glutamate by Na+-dependent glutamate transporters
(Anggono and Huganir, 2012). Layered upon this are the more
recently discovered inﬂuences of glial-derived glutamate release
and uptake and extrasynaptic mGluRs on excitatory synap-
tic transmission and plasticity (Kalivas et al., 2009). Although
this review focuses on MOR-mediated modulation of AMPAR
and NMDAR-mediated glutamatergic transmission, it is essen-
tial to understand that glutamate homeostasis (regulation of
synaptic and perisynaptic extracellular glutamate levels) requires
ionotropic and metabotropic (mGluR) receptors as well as a del-
icate balance between glial and synaptic glutamate release and
elimination. Comprehensive reviews of glutamate homeostasis in
the context of drug addiction are available (Kalivas, 2009; Kalivas
et al., 2009).
AMPA RECEPTORS
AMPARs are a subgroup of ionotropic glutamate receptors found
at most excitatory synapses, are activated at resting membrane
potential, and are considered the primary postsynaptic mediators
of glutamate transmission in the NAc (Cherubini et al., 1988).
AMPARs comprise four subunits (GluR1–4) that assemble in
various combinations to form tetramers (Seeburg, 1993; Holl-
mann and Heinemann, 1994; Dingledine et al., 1999). GluR1–4
share ∼70% sequence homology and differ primarily due to post-
transcriptional modiﬁcations, which confer unique properties to
the subunits. For example, the GluR2 transcript undergoes RNA
editing such that a glutamine residue in the channel-forming seg-
ment of the receptor is converted to an arginine (Sommer et al.,
1991). This renders GluR2-containing AMPARs impermeable to
Ca2+ (Burnashev et al., 1992). Given that AMPARs exist primar-
ily as GluR1–2 and GluR2–3 populations (Wenthold et al., 1996),
most AMPARs gate Na+ but not Ca2+. However, synaptic activ-
ity – including in vivo experience – can shift the stoichiometry
of synaptic AMPAR subunit composition toward GluR2-lacking
receptors (Liu and Cull-Candy, 2000; Takahashi et al., 2003; Ju
et al., 2004; Clem and Barth, 2006), and increasing GluR1 expres-
sion favors formation of GluR1-homomeric AMPARs that allow
Ca2+ ﬂux (Hollmann et al., 1991).
Trafﬁcking of AMPARs into and out of synapses determines
the level of excitatory synaptic strength and is a major mechanism
of plasticity underlying learning (Malinow and Malenka, 2002).
AMPARs can be endocytosed and exocytosed into perisynaptic
regions, and they can also be shuttled laterally along the surface
of the neuronal membrane between synaptic and extrasynaptic
compartments (Heine et al., 2008). A host of AMPAR auxiliary
subunits such as transmembrane AMPAR regulatory proteins
(TARPs), Cornichon proteins, Neuropilin, and Tolloid-like pro-
teins (Netos) are necessary for the dynamics of AMPAR subcellular
localization (Straub and Tomita, 2012). Heteromers containing
GluR2–3 subunits are constitutively recycled and maintain basal
AMPAR transmission, whereas heteromers containing GluR1–2
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FIGURE 1 | Interactions between MOR and glutamatergic
neurotransmission in the nucleus accumbens (NAc). MORs are coupled
to inhibitory Gα i proteins and are found on glutamatergic and GABAergic
terminals and postsynaptically on (primarily) D1 receptor-expressing MSNs.
Acute opioids: Acute MOR activation in a naïve animal suppresses GABA and
glutamate release via inhibition of Ca2+ and activation of K+ conductances,
as well as inhibition of cAMP-mediated activation of non-selective cation
pacemaker currents (Ih). Postsynaptic NMDAR currents are augmented via
MOR-induced PKC activation. There is no known data on the acute,
immediate effects of opioids on AMPAR expression/localization/function in
naïve animals. Chronic opioids: Inhibitory effect of presynaptic mGluR2/3
receptors to inhibit glutamate release is increased during chronic opioid
treatment. Surface expression of GluR1 subunits is decreased on MSNs,
with no change in total AMPAR subunit expression. Levels and/or function of
the NR2A NMDAR subunit are increased, which may contribute to a
decreased afﬁnity for the co-agonist glycine and a decreased sensitivity to
PKC-mediated NMDAR activation. Opioid withdrawal : Extracellular glutamate
levels are increased, but synaptic transmission may be reduced via enhanced
mGluR2/3 autoreceptor function. GABA release is potentiated via augmented
cAMP and PKA pathways. NR2B surface expression is increased, perhaps
resulting in an increase in silent synapses devoid of AMPARs. Upregulated
cAMP and PKA signaling leads to increased P-GluR1Ser845, which may prime
AMPARs containing GluR1 at the plasma membrane to be shuttled to
synapse upon CaMKII activation. PfC, prefrontal cortex; VSub, ventral
subiculum; BlA, basolateral amygdala; MSN, medium spiny
neuron.
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FIGURE 2 | Interactions between MOR and glutamatergic
neurotransmission in the ventral tegmental area (VTA). Acute opioids:
Acute MOR activation in a naïve animal inhibits glutamatergic neurons via
arachidonic acid-dependent potentiation of voltage-dependent K+ channels.
GABA neurons are inhibited via G protein-mediated inhibition of Ca2+ and
activation of K+ conductances, and GABA release is decreased via
inhibition of cAMP-dependent facilitation of transmitter release. This leads
to disinhibition of dopamine neurons and increased somato-dendritic
dopamine release. Stimulatory dopamine D5 receptors on dopamine
neurons are activated and, in conjunction with CaMKII, facilitate increased
surface expression of GluR1 subunits. Chronic opioids: Dopamine ﬁring rate
remains elevated. Tolerance to inhibitory effects of MOR activation on
GABAergic neurons develops through compensatory upregulation of cAMP
systems, but dopamine neuron K+ channels are downregulated, enabling
increased basal ﬁring rate and burst activity of dopamine neurons. Total and
surface GluR1 is increased and NR1 subunits are increased. Opioid
withdrawal : Activity of GABA neurons is increased due to disinhibition of
Ca2+ channels and reduced activation of K+ channels. GABA release is
increased due to unmasking of upregulated cAMP systems. Extracellular
glutamate levels are increased, but inhibitory presynaptic GABAB and
mGluR2/3 receptor function is enhanced, leading to decreased synaptic
release of glutamate. RMTG, rostromedial tegmental nucleus; PPTg,
pedunculopontine tegmental nucleus, BNST, bed nucleus of the stria
terminalis; DA, dopamine.
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FIGURE 3 | Naloxone-precipitated morphine withdrawal increases
GluR1 phosphorylation in a PKA-dependent manner. (A) Rats were
subcutaneously implanted with morphine (2 × 75 mg) or placebo pellets
and returned to their home cages for 3 days in order for morphine
dependence to develop. Naloxone (0.0, 0.01, or 1.0 mg/kg, SC) was
injected and rats killed 30 min later. Brains were removed and frozen,
1-mm3 punches of the NAc were extracted, and P-GluR1Ser845 and β-actin
(protein loading control) were quantiﬁed on immunoblots. Data are
expressed as fold-induction of P-GluR1/actin levels relative to
non-dependent (placebo) rats treated with vehicle. *p < 0.05, **p < 0.01
compared to non-dependent (placebo) rats treated with vehicle. ∧p < 0.05
comparing groups under bar. N = 5–9 rats/group. Modiﬁed from Chartoff
et al. (2006). (B) PKA is required for super-induction of P-GluR1Ser845 during
naloxone-precipitated morphine withdrawal. Primary striatal cultures were
treated chronically with either vehicle or morphine (morph, 10 μM) for 6
days, followed by a 1.5-h treatment with vehicle [dimethylsulfoxide (DMSO)]
or the PKA inhibitor H89 (20 μM), followed by a 30-min incubation with
vehicle or naloxone (nal, 10 μM), and the dopamine D1 receptor agonist
SKF 82958 (SKF, 50 μM) for 15 min. The ratio of P-GluR1Ser845/actin was
determined for each sample and normalized to the control group ratio to
yield a fold induction. Data are plotted as the mean fold induction ± SEM.
*p < 0.05, **p < 0.01 compared with control. ∧p < 0.05, ∧∧p < 0.01
comparing groups designated by solid lines. N = 3 experiments with
treatments in triplicate (see Chartoff et al., 2003a for details).
subunits are delivered to synapses in a precisely regulated manner
and are critical for experience-dependent plasticity (see Mali-
now and Malenka, 2002). In the absence of activity, synapses
can be devoid of GluR1–2-containing AMPARs. PKA-mediated
phosphorylation of GluR1 at Ser845 (P-GluR1Ser845) enhances
channel conductance and open probability, and in combina-
tion with activity-dependent Ca2+ signaling (e.g. via NMDARs),
phosphorylation can drive GluR1 into synapses, which could
allow synaptic strengthening (Esteban et al., 2003). Importantly,
P-GluR1Ser845 is necessary but not sufﬁcient for trafﬁcking of
GluR1 subunits to synapses (e.g. Figure 2, Chronic condition).
In the NAc, this type of plasticity might involve convergence
of dopamine and glutamate inputs (Wolf et al., 2003): activa-
tion of postsynaptic D1 receptors induces P-GluR1Ser845 and
activation of NMDARs could allow synaptic delivery. Con-
versely, activation of AMPARs can lead to compensatory dephos-
phorylation of GluR1 and subsequent removal from synaptic
zones to intracellular vesicles (Beattie et al., 2000; Snyder et al.,
2003).
Synaptic scaling is a homeostatic form of plasticity in which
prolonged activity or lack of activity atAMPARs (∼1–3 days) leads
to compensatory decreases or increases, respectively, in synaptic
AMPAR levels (Turrigiano, 2008). This phenomenon is thought to
stabilize neuronal activity during periods of abnormal or patho-
logical activity, and may be highly relevant to addiction and drug
withdrawal.
NMDA RECEPTORS
NMDARs are a subgroup of ionotropic glutamate receptors found
throughout the brain that act – in concert with colocalized
AMPARs – as synaptic coincidence detectors to facilitate learn-
ing and memory (Tang et al., 1999; Citri and Malenka, 2008).
NMDARs exist as heterotetramers composed of two NR1 sub-
units and two subunits from the NR2 or NR3 family (Seeburg
et al., 1995). NR1 subunits are expressed ubiquitously in the brain,
whereas NR2 subunits are spatially localized (Dunah et al., 1999).
The basal forebrain (includes the NAc) is enriched for NR2A
and B, with a predominance of NR2B in NAc medium spiny
neurons (MSNs; Chen and Reiner, 1996; Kuppenbender et al.,
2000). NMDARs are unique in that they require both ligand
(glutamate) binding and membrane depolarization (to release
extracellular Mg2+ block) in order to be activated. Once acti-
vated, NMDARs conduct both Na+ and Ca2+, which results
in excitatory postsynaptic currents (EPSCs) with greater mag-
nitude and longer half-life than those from AMPARs that pass
only Na+. Perhaps most importantly, NMDAR activation engages
Ca2+-mediated signal transduction pathways that can have long-
lasting effects on gene expression, post-translationalmodiﬁcations
of proteins (e.g., phosphorylation), and voltage-gated ion chan-
nels (Hyman et al., 2006). In fact, Ca2+ inﬂux is required for
NMDAR-mediated long-term potentiation (LTP). The NR1 sub-
unit is essential for channel function whereas NR2 subunits
control channel gating and Mg2+ dependency (Monyer et al.,
1992).
Anatomical studies have shown that MORs and NMDARs
colocalize on single neurons in many brain regions, including
within the dorsal striatum and NAc shell (Trujillo, 2002; Glass
et al., 2009). More recently, immunoprecipitation analysis has
revealed that MORs can directly interact with NMDA NR1 sub-
units (Rodriguez-Munoz et al., 2012). This patternwas observed in
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the PAG, cerebral cortex, striatum, and dorsal spinal cord, suggest-
ing functional interactions between MOR and NR1 are important
for analgesic and affective responses to opioids.
The importance of NMDARs to opioid dependence and the
OWS may lie in the well established role of NMDARs in form-
ing associative memories via their ability to detect two coincident
synaptic events at the cellular level (i.e., LTP; long-term depres-
sion, LTD). This type of learning is thought to be important for
phenomena such as conditioned craving and conditioned with-
drawal, which are common in abstinent opiate addicts and are
major triggers of relapse. There is also evidence that NMDAR-
mediated plasticity is necessary for extinction of drug-associated
memories. Speciﬁcally, the NMDAR partial agonist, D-cycloserine
(DCS) facilitates extinction of morphine withdrawal-associated
place aversions in morphine-dependent rats (Myers and Car-
lezon,2010a) and extinction of cocaine-induced conditioned place
preferences (Botreau et al., 2006; Paolone et al., 2009).
Although NMDARs are classically thought of as a major sub-
strate for Hebbian learning, they can also have unconditioned
effects on reward and affective states. For example, rats will self-
administer competitive andnon-competitiveNMDARantagonists
directly into the NAc (Carlezon and Wise, 1996b), and NMDAR
antagonists potentiate brain stimulation reward (Carlezon and
Wise, 1996a). These ﬁndings suggest that a reduction in the over-
all excitability of neurons in the NAc (via NMDAR blockade)
and/or a reduction in intracellular Ca2+ signaling is sufﬁcient for
reward. It is likely that NMDAR-mediated increases in synaptic
strength (learning) and changes in affective state are not mutu-
ally exclusive processes. One can envision a scenario during drug
withdrawal in which the experience of an intense dysphoric state is
stamped into memory through NMDAR activation in select brain
regions. This idea will be discussed in more detail in the following
sections.
NUCLEUS ACCUMBENS
The NAc (ventral striatum) can be subdivided into multiple terri-
tories based on functional connectivity and neuronal phenotypes
(Zahm and Brog, 1992). The NAc core is a central portion of
the ventral striatum that surrounds the anterior commissure and
is a functional continuation of the neighboring dorsal striatum.
It has been shown to be particularly important for instrumen-
tal learning such as cue-induced reinstatement of drug seeking
(McFarland and Kalivas, 2001). The shell comprises the most
ventral and medial portions of the NAc, and has an important
role in drug reward, motivated behavior, behavioral sensitiza-
tion, and changes in affective state. In addition, subterritories
such as the rostral pole, cone and intermediate zone of the
NAc shell have been described (Zahm and Brog, 1992). A long-
standing conception is that the NAc is a “motivation to movement
interface” (Mogenson et al., 1980), and accumulating evidence
has conﬁrmed this idea by identifying the neural circuits that
loop from limbic and cognitive cortical regions to motor out-
put regions (Haber and Knutson, 2010). Thus, the NAc is a
key site for transference of motivational and emotional signals
to adaptive behavioral responses. Despite its long tenure as the
“reward center” of the brain, increasing evidence supports the
idea that the NAc is a bivalent structure that processes positive
and negative emotional stimuli into either approach or avoidance
behavior (Becerra et al., 2001; Reynolds and Berridge, 2002; Jensen
et al., 2003; Roitman et al., 2005; Carlezon and Thomas, 2009).
This has important ramiﬁcations for understanding addiction,
since drugs of abuse provide hyperbolic positive (drug “high”)
and negative (drug withdrawal, “crash”) emotional signals to the
NAc.
AFFERENTS
Consistent with the view that the NAc gates rewarding and aver-
sive stimuli and directs subsequent goal-directed behavior, NAc
afferents come from brain regions known to be important for
processing both positive and negative emotional stimuli, such as
the basolateral amygdala (Kelley et al., 1982) and for goal-directed
behavior, including the orbitofrontal cortex, insula, cingulate cor-
tex (Berendse et al., 1992), andmidline and intra-laminar thalamic
nuclei (Berendse and Groenewegen, 1990). In addition, the NAc
receives rich innervation from the ventral subiculum of the hip-
pocampus (Kelley and Domesick, 1982; Groenewegen et al., 1987),
which likely provides spatial and contextual information about
the stimuli (for review of NAc afferents, see Brog et al., 1993;
Sesack and Grace, 2010). The vast majority of NAc afferents
are glutamatergic and provide the excitatory drive necessary to
evoke behavior. The NAc also receives some inhibitory, GABAer-
gic inputs from the ventral pallidum and the VTA, as well as local
inhibitory connections from within the striatum (Brog et al., 1993;
Sesack and Grace, 2010). Layered on top of fast neurotransmis-
sion controlled by glutamate and GABA, the output of the NAc
is modulated by robust networks of neuropeptides, both intrin-
sic and extrinsic to the NAc. These include, but are not limited
to, orexin, dynorphin, enkephalin, substance P, and neurotensin
(Hokfelt et al., 2000). Finally, dopamine afferents from the VTA
provide an essential component of reward processing in the NAc.
Dopaminemodulates the general excitability of NAc neurons, thus
increasing or decreasing behavioral output based on the level of
emotional salience coded by the dopamine input (Koob, 1992;
Ikemoto and Panksepp, 1999; Wise, 2004).
INTRINSIC SIGNALING
Within the NAc, GABA-containing medium spiny output neu-
rons comprise the majority (∼90–95%) of neurons (Wilson and
Groves, 1980; Gerfen, 1992), with the remaining cells being either
GABAergic or cholinergic interneurons (Kawaguchi et al., 1995).
The function of MSNs depends on their particular inputs and out-
puts, but also on the phenotype of the MSN itself. Only recently
have researchers had the tools to begin to dissect the complex
microcircuitry of the NAc. As with the dorsal striatum,NAc MSNs
can be broadly divided into dopamineD1-like (includesD1 andD5
receptors) or dopamine D2-like (includes D2, D3, and D4) recep-
tor expressing circuits (Gerfen et al., 1990; Lobo, 2009). MSNs
express different constellations of neuropeptides, with dynorphin
often co-expressing with dopamine D1 receptors and enkephalin
with dopamine D2 receptors (Gerfen et al., 1990; Lobo, 2009). In
the NAc, MORs are expressed primarily by dynorphin- and D1
receptor-expressing cells (Georges et al., 1999).
Glutamate neurotransmission is kept under tight control:
too much or too little can have devastating effects (Kalivas,
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2009), whereas stimulus-dependent changes in glutamatergic
transmission are necessary for learning (Kauer and Malenka,
2007). Structurally, synaptic input to MSNs is arranged such
that glutamatergic afferents synapse on dendritic spines and
modulatory inputs such as dopamine make connections extra-
synaptically on dendritic shafts. This triad of spine, glutamate
synapse and dopamine synapse allows dopamine to modu-
late the general excitability of NAc neurons (Surmeier et al.,
2007; Sesack and Grace, 2010). Glutamatergic activation of
NAc MSNs is mediated primarily by AMPARs (Hu and White,
1996). Approximately 90% of AMPARs in the NAc are made
of GluR1 and GluR2 or GluR3 containing tetramers with only
about 6% being GluR1–3 complexes (Wolf, 2010; Reimers et al.,
2011). There is some evidence for a very small percentage
of AMPARs in the NAc to exist as GluR1 homomers. Func-
tionally, this implies that the vast majority of NAc AMPARs
conduct Na+ but not Ca2+, given that GluR2 renders AMPARs
impermeable to Ca2+. NMDARs play a critical role in tagging
connections that receive convergent glutamate and dopamine
inputs. For example, cortical excitation of selected MSNs in
the presence of dopamine would lead to an increase in synap-
tic strength in a two-step process: activation of postsynaptic
D1 receptors induces PKA-dependent P-GluR1Ser845 and activa-
tion of NMDARs facilitates synaptic delivery of GluR1 (Wolf,
2010).
EFFERENTS
The functional consequences of glutamate transmission in theNAc
are being elucidated: in general, NAc neurons are activated in
response to aversive stimuli and inhibited in response to reward-
ing stimuli (Peoples and West, 1996; Carelli, 2002; Roitman et al.,
2005). GABAergic MSNs from the NAc project to the ventral pal-
lidum, substantia nigra (SN), VTA, hypothalamus, and brainstem
(Haber et al., 1990). There is topographical organization such that
a medial (i.e., shell) to lateral (i.e., core/dorsal striatum) series of
projection loops allows emotion-based information from limbic-
associated structures to transfer to motor-related areas of the basal
ganglia (Haber et al., 2000). Within these spiraling loops, some
NAc outputs – particularly in the core – are functionally analo-
gous to the direct and indirect pathways described for the dorsal
striatum (Sesack and Grace, 2010). Activation of Gαs-coupled D1-
like receptors stimulates production of cAMP and tends to excite
MSNs that project directly back to the VTA and the ventral pal-
lidum (direct pathway), whereas activation of Gαi-coupledD2-like
receptors inhibits cAMP production and tends to inhibit MSNs
that selectively project to the ventral pallidum (indirect pathway;
Lu et al., 1998; Surmeier et al., 2007). Thus, cortical activation
of the direct pathway leads to disinhibition of motor circuits
that enable reward acquisition whereas activation of the indi-
rect pathway inhibits motor circuits that are maladaptive (Mink,
1996).
VENTRAL TEGMENTAL AREA
The VTA has been extensively studied for its role in reward and
addiction. Opioids are self-administered directly into the VTA
(Bozarth and Wise, 1981; Devine and Wise, 1994), while blockade
of VTA MORs suppresses heroin self-administration (Britt and
Wise, 1983). Intra-VTA morphine injections produce conditioned
place preferences (Bozarth, 1987), enhance the rewarding impact
of intracranial self-stimulation (Broekkamp et al., 1976), and rein-
state extinguished lever pressing for heroin (Stewart et al., 1984).
Dopamine neuronsmake up about 60–65%of the cells in theVTA,
with GABAergic (∼25%) and glutamatergic (up to 15%) neurons
making up the rest (Swanson, 1982; Nair-Roberts et al., 2008).
Most classes of drugs of abuse increase dopamine release in effer-
ent targets of theVTA, including theNAc (DiChiara and Imperato,
1988a). Comprehensive reviews of the role of VTA dopamine in
reward function and addiction have been published (Berridge and
Robinson, 1998; Wise, 2004; Fields et al., 2007; Ikemoto, 2007;
Wheeler and Carelli, 2009; Salamone and Correa, 2012), with the
emerging view that not only does dopamine mediate the positive
reinforcing effects of drugs but it is also instrumental in learning
how particular behaviors lead to reward or aversion (Volman et al.,
2013).
AFFERENTS
TheVTA is regulated by an integrated network of excitatory inputs
arising from the PFC, the pedunculopontine region (PPTg), the
laterodorsal tegmentum (LDTg), and the sub thalamic nucleus
(Grace et al., 2007). These connections are organized in the sense
that glutamatergic inputs from the medial PFC (mPFC) synapse
on dopamine neurons that project back to the mPFC but not on
those that project to the NAc (Carr and Sesack, 2000). The VTA
and the more caudal“tail”of theVTA (RMTg) receives GABAergic
input from the lateral habenula, NAc shell, and ventral pallidum
(Zahm and Heimer, 1990; Jhou et al., 2009). Importantly, the
RMTg provides tonic GABAergic inhibition of VTA dopamine
neurons that keeps them in a pacemaker-type ﬁring pattern in the
absence of stimulation (Bourdy and Barrot, 2012). The transition
from pacemaker-like ﬁring of dopamine neurons to burst ﬁring,
which is thought to represent a phasic dopamine response asso-
ciated with reward and reward-related cues, requires glutamate
input from the PPTg–LDT complex (Floresco et al., 2003; Lodge
and Grace, 2006; Grace et al., 2007).
INTRINSIC SIGNALING
GABA neurons of the VTA and RMTg express dense MOR mRNA
and immunoreactivity (Mansour et al., 1988, 1995a; Garzon and
Pickel, 2001; Svingos et al., 2001; Jhou et al., 2009). Morphine
indirectly excites dopamine neurons via inhibition of these GABA
neurons that synapse on dopaminergic dendrites in the VTA
(Johnson and North, 1992; Jalabert et al., 2011). This disinhibition
of dopamine neurons requires NMDAR and AMPAR activation
(Jalabert et al., 2011). Taken together, the effects of opioids onVTA
function involve a close interaction between postsynaptic MORs
and glutamate signaling.
EFFERENTS
There is a topographical organization to the VTA, with dopamine
and GABAergic efferents having a medial to lateral projection to
output structures such as theNAc, PFC,cingulate cortex, andbaso-
lateral amygdala (Ikemoto, 2007). In addition, there is a rostral
to caudal organization in which the ratio of dopamine to GABA
decreases caudally (Bourdy and Barrot, 2012). In broad terms,
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there are stronger drug reward associations in the caudal-medial
versus anterior VTA (Ikemoto, 2007).
ACUTE OPIOIDS
CLINICAL DESCRIPTION
The National Survey on Drug Use and Health (NSDUH, 2013),
the National Monitoring the Future survey study (Johnston et al.,
2014), and the Columbia CASA report (The National Center
on Addiction and Substance Abuse, Columbia University, 2011)
provide consistently alarming trends of early age initiation of pre-
scription opioid misuse (1.5% of children age 12–13 years old
used in the prior month) and heroin use, with a national average
age of opioid initiation between 22 and 23 years old. Teenagers
report high availability of illicit opioids: 20 and 45% of high
school seniors report it is easy to get heroin and prescription opi-
oids, respectively (Johnston et al., 2014). Teens report using both
to get high and to relieve tension, despite pervasive disapproval
and perceived risk (The National Center on Addiction and Sub-
stance Abuse, Columbia University, 2011). Teens describe being
high on opioids as, “the best feeling ever,” or, “I ﬁnally felt happy,”
which is not different from the self-reported experiences of adult
initiates.
MOR–GLUTAMATE INTERACTIONS IN THE NAc (see Figure 1)
Acute administration of opioids activates MORs and increases
extracellular dopamine in the NAc (Figure 1, yellow ovals; Di
Chiara and Imperato, 1988a). However, dopamine is not neces-
sary for the acute rewarding effects of opiates in non-dependent
animals, as dopamine receptor blockade or 6-hydroxydopamine
(6-OHDA)-mediated dopamine denervation of the NAc does not
prevent heroin self-administration (Pettit et al., 1984; Gerrits and
Van Ree, 1996). Even evidence demonstrating a requirement for
the NAc in opiate reward and reinforcement is equivocal. For
example, mice can learn to self-administer MOR agonists directly
into the NAc (Goeders et al., 1984; David and Cazala, 2000),
and yet intra-NAc morphine fails to produce conditioned place
preferences in rats (Schildein et al., 1998). Lesions or inactiva-
tion of the NAc partially reduce opiate self-administration (Zito
et al., 1985; Dworkin et al., 1988; Alderson et al., 2001), but it is
difﬁcult to interpret the meaning of these data on their own,
since a decrease in the number of drug infusions at a single
drug dose can mean either a decrease or an increase in the rein-
forcing efﬁcacy of a drug (Mello and Negus, 1996). A study
showing that NAc lesions reduced progressive ratio (PR) respond-
ing for morphine in rats (Suto et al., 2011) supports the idea that
the NAc plays a role in the motivation to work for morphine.
Yet direct infusions of MOR antagonists into the NAc actually
increase heroin self-administration (Vaccarino et al., 1985), which
the authors interpret as a decrease in the reinforcing efﬁcacy of
heroin driving increased drug-taking. Thus, the NAc can mod-
ulate opioid reward and drug-taking behavior, but its precise
role is complicated by prior drug experience and method of
administration.
Human imaging studies have generally shown that, in drug-
experienced people, an immediate (i.e., during the “rush”) effect
of opioid administration is an increase in regional cerebral blood
ﬂow in the anterior cingulate cortex, thalamus, and amygdala
(Schlaepfer et al., 1998; Kosel et al., 2008). In contrast, after the
initial “rush” has subsided and the longer lasting euphoric effects
of acute opioids emerge, blood ﬂow tends to be decreased (London
et al., 1990; Denier et al., 2013). This is consistentwith electrophys-
iological and neurochemical ﬁndings in rats, in which systemic
morphine inhibits spontaneous ﬁring of a majority of neurons
in the mPFC (Giacchino and Henriksen, 1996). In many neu-
rons, MOR-mediated inhibition of adenylate cyclase results in
a decrease in cAMP-dependent activation of voltage-dependent
Ih pacemaker currents (Figure 1, GABAergic neurons, Acute
condition; Williams et al., 2001). A decrease in cAMP shifts the
voltage dependence to more negative potentials, making it harder
to depolarize the neuron. MOR activation suppresses basal and
evoked increases in extracellular glutamate in the NAc and dorsal
striatum (Figure 1, glutamate neurons, Acute and Chronic con-
ditions; Desole et al., 1996; Enrico et al., 1998; Sepulveda et al.,
2004). Although the functional consequences of changes in cere-
bral blood ﬂow and cortical activation are not yet known, the
ﬁndings suggest that opioid-induced reward is associated with
decreased cortical activity and potentially decreased glutamatergic
input to downstream NAc MSNs. Despite the evidence for opiate
modulation of glutamate release in the NAc, there is relatively
little data on the role AMPAR and NMDAR play in mediating
the acute rewarding effects of opiates. This is surprising, given
the previously discussed ﬁndings that acute opiates have pro-
found effects on glutamatergic projections to the NAc and that
the activation state of MSNs plays an important role in affect
and emotional responses to stimuli (Roitman et al., 2005; Car-
lezon and Thomas, 2009). One prediction, based on synaptic
scaling (Turrigiano, 2008), is that opiate-induced decreases in
glutamatergic transmission to the NAc would result in increased
surface expression of AMPARs. There are no known studies that
address this prediction directly. Rather, there is evidence that
expression of NMDAR and AMPAR subunits is decreased in the
NAc core 3 days after acute morphine exposure (Jacobs et al.,
2005). Similarly, there is one study that reports a decrease in
surface levels of NAc GluR1 24 h after an acute morphine injec-
tion (Herrold et al., 2013). Unfortunately this time course does
not actually reﬂect the acute rewarding effects of morphine but
may rather reﬂect a state of acute withdrawal (Rothwell et al.,
2012).
Using intracellular recordings from NAc slice preparations, it
has been reported that acute MOR activation depresses NMDA
and non-NMDA (presumably AMPA) excitatory postsynaptic
potentials (EPSPs) in the NAc through a presynaptic mechanism
involving reductions in spike-generated Ca2+ currents (Martin
et al., 1997). A general effect of MOR activation that could account
for this is inhibition of presynaptic voltage-gated Ca2+ channels
(L-, N-, P/Q-, R-) through Gαo–βγ subunits (see Figures 1 and
2, presynaptic glutamatergic neuron, Acute condition; Law et al.,
2000). Although this would predict a decrease in MSN activation,
this study also demonstrated that postsynaptic NMDA currents
were augmented via a protein kinase C (PKC)-dependent mecha-
nism (Figure 1, postsynapticGABAneuron,Acute condition). The
ultimate consequences of these opposing MOR actions are still not
fully understood. A more recent study in awake and behaving rats
showed that a non-contingent injectionof heroin produced a small
www.frontiersin.org May 2014 | Volume 5 | Article 116 | 9
Chartoff and Connery MOR–glutamate crosstalk in mesolimbic system
decrease (not signiﬁcant) in extracellular glutamate in the core in
drug-naïve rats (LaLumiere and Kalivas, 2008). Taken together,
the available data suggest that acute opiates decrease glutamate
release in the NAc in non-dependent animals, which is consistent
with the general ﬁnding that decreases in NAc MSN activation are
associated with reward-like states (Carlezon and Thomas, 2009).
MOR–GLUTAMATE INTERACTIONS IN THE VTA (see Figure 2)
An immediate effect of an acute opiate injection is inhibition of
MOR-containing GABAergic neurons (Figure 2, GABAergic neu-
ron, Acute condition) in the RMTg that make strong synaptic
contacts on the soma and dendrites of dopamine neurons and a
subsequent decrease in LTP of these GABAergic synapses (John-
son and North, 1992; Niehaus et al., 2010; Jalabert et al., 2011;
Mazei-Robison et al., 2011). A second immediate effect is a presy-
naptic inhibition of glutamatergic afferents via MOR-mediated,
arachidonic acid-dependent, activation of voltage-sensitive K+
channels (Figure 2, Glutamate neuron, Acute condition; Manzoni
and Williams, 1999). This effect on glutamate release is confusing,
because onewould expectmorphine to produce rapid activation of
dopamine neurons through both inhibition of GABA inputs and
excitation of glutamatergic inputs. In fact, it has been reported
that an opiate-dependent increase in AMPAR activation in the
VTA is required for disinhibition of dopamine neurons (Gysling
and Wang, 1983; Di Chiara and Imperato, 1988a; Jalabert et al.,
2011). Although not fully understood, the issue is likely related to
timing.
An acute response common to most classes of drugs of
abuse, including opiates, is an increase in AMPA transmission
in dopamine neurons measured 24 h after acute administra-
tion of drug (Ungless et al., 2001; Saal et al., 2003; Brown et al.,
2010). This is thought to be due to an increase in surface
expression of AMPARs. Since acute morphine inhibits activity of
glutamatergic afferent neurons (Giacchino and Henriksen, 1996;
Manzoni and Williams, 1999), this observed increase in evoked
AMPA transmission may not immediately translate to increased
excitation of the VTA. Rather, morphine-induced decreases in
glutamate release to the VTA may promote compensatory, postsy-
naptic increases in AMPA signaling that produce LTP at select
synapses. Consistent with this, an increase in surface expres-
sion of GluR1 in the VTA (Figure 2, Dopamine neuron, Acute
condition) has been reported 24 h (Brown et al., 2010), and as
early as 1 h (Lane et al., 2008), after morphine injection. The
mechanism through which morphine increases GluR1 synaptic
insertion and LTP is not fully understood, but is thought to involve
stimulation of dopamine D5 receptors (Figure 2, Dopamine neu-
ron, Acute condition), which belong to the Gαs-coupled D1-like
receptor family (Schilstrom et al., 2006; Brown et al., 2010). D5,
unlike D1, receptors are expressed on dopamine neurons of the
VTA (Weiner et al., 1991; Khan et al., 2000). Thus, morphine-
induced dopamine release can stimulate D5 receptors in the
VTA, which would activate cAMP-dependent processes including
PKA-dependent phosphorylation of GluR1. Phosphorylation of
GluR1 facilitates synaptic insertion and increases synaptic current
(Kessels and Malinow, 2009), providing a potential mechanism for
feed-forward enhancement of morphine’s actions on dopamine
neurons. Consistent with this, overexpressing GluR1AMPAR sub-
units in the VTA sensitizes rats to the locomotor effects of acute
morphine and potentiates morphine-induced conditioned place
preferences (Carlezon et al., 1997). Although GluR1 trafﬁcking
is evident after only one injection of morphine, it is thought
that the cumulative effects of repeated morphine treatment are
necessary for the plasticity in dopamine neuron excitability that
contribute to the development of sensitization (Carlezon and
Nestler, 2002).
A critical role for VTA AMPA and NMDARs in acute opiate
reward has been demonstrated in behavioral studies. Intra-VTA
delivery of an NMDAR or an AMPAR antagonist increased heroin
self-administration in the same manner that decreasing the avail-
able dose of heroin does (Xi and Stein, 2002). This is consistent
with the idea that NMDA and AMPAR activation is necessary for
the acute reinforcing effects of opioids. Intra-VTA blockade of
either NMDAR or AMPAR decreases both the acquisition and
expression of morphine conditioned place preferences (Harris
et al., 2004). Place conditioningdependsuponan associativemem-
ory of the pairing of an affective state (reward or aversion) with
a context. Thus, the role of VTA glutamate transmission in opiate
effects could be to promote associative learning and/or to promote
a rewarding state that has salience as an unconditioned stimulus
in the place conditioning paradigm.
CHRONIC OPIOIDS
CLINICAL DESCRIPTION
Most individuals who are recently opioid-dependent are not fully
aware they are “hooked.” Getting high is still euphoric, and mild
withdrawal symptoms are surprising and manageable. Cognitive
appraisal is, “I can stop if I need to.” Seeking a more intensive high
may lead the individual to change to a route of administration that
produces a more rapid and potent effect (e.g. oral to intranasal,
or intranasal to intravenous), to try a more potent formulation
(switching analgesics or getting a “good batch” of heroin), or to
mixing opioid use with other substances, particularly sedative-
hypnotics.
Opioids can be administered chronically in a number of ways
(steady dosing of extended release painkillers, repeated intermit-
tent abuse, binge-type self-administration, or any combination
of the preceding), which likely inﬂuences the resulting neural
adaptations. As discussed above, an additional consideration in
interpreting data from chronic drug studies is the time point
at which molecular or behavioral measures are taken. Effects
observed 24 h or more after the end of a chronic drug regi-
men may more accurately reﬂect drug withdrawal rather than
chronic effects per se. Furthermore, accumulating evidence sug-
gests that GPCRs (e.g., MOR) modulate synaptic activity on a
timescale that extends well beyond that of initial receptor activa-
tion, resulting in a metaplasticity that can either lower or raise
the threshold for induction of LTP-like processes (Tenorio et al.,
2010).
MOR–GLUTAMATE INTERACTIONS IN THE NAc
Chronic activation of MORs triggers counteradaptions in cAMP
signaling such that adenylate cyclase function is enhanced (Nestler
and Aghajanian, 1997; Williams et al., 2001). The presence of
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chronic opioids masks the effects of increased cAMP, but it
alters how other GPCRs signal through adenylate cyclase. As
one example, chronic morphine increases the inhibitory efﬁcacy
of presynaptic mGluR2/3 receptors on glutamate release in the
NAc (Figure 1, Glutamatergic neuron, Chronic condition; Mar-
tin et al., 1999). This may evolve from an increased functional
connectivity between mGluR2/3 receptors and upregulated cAMP
signaling.
Numerous studies have examined effects of repeated psy-
chostimulants (contingent and non-contingent administration
protocols) onAMPAR-mediated synaptic transmission in the NAc
(Wolf et al., 2004; Luscher, 2013; Pierce and Wolf, 2013). Unfor-
tunately, relatively little is known about effects of chronic opioids.
These types of studies are important, because available research
has shown that cellular and structural consequences of opioids
often differ from those of psychostimulants (Badiani et al., 2011).
Chronic, steady state levels of morphine achieved with subcuta-
neous morphine pellet implants do not change total protein levels
of AMPAR subunits (Chartoff et al., 2006), although this does not
take into account changes in subcellular localization. To address
this, Glass et al. (2008) used immunogold ultrastructural analy-
sis to demonstrate that surface expression of GluR1 subunits is
decreased after chronic morphine treatment (1 h after 14 days
of non-contingent injections; Figure 1, postsynaptic GABA neu-
ron, Chronic condition). This effect was localized to dopamine D1
receptor-expressing neurons in the NAc shell and in all MSN types
in the core. In contrast, a different opiate regimen (1 day after 1
injection/day for 3 days) produced no change in subcellular distri-
bution of either GluR1 or 2 in the NAc (Mickiewicz and Napier,
2011). The mechanisms by which chronic opioids modulate sub-
cellular distribution of AMPAR subunits are not known. However,
given that activation of MORs inhibits adenylate cyclase and cAMP
production, it is possible that the resulting brake on PKA function
leads to decreased P-GluR1Ser845 in the NAc (Figure 1, postsy-
naptic GABA neuron, Chronic condition), which would favor
internalization processes (Song and Huganir, 2002; Mangiavacchi
and Wolf, 2004). This is consistent with formation of LTD, which
requires clathrin-dependent endocytosis of postsynaptic AMPARs
(Brebner et al., 2005).
More is known about the effects of chronic morphine on
NMDAR-mediated synaptic transmission in the NAc compared
to AMPA transmission. As discussed above, acute morphine’s
actions in the NAc include presynaptic inhibition of glutamate
release as well as a postsynaptic potentiation of NMDAR EPSPs via
activation of PKC (Martin et al., 1997). Postsynaptically, chronic
morphine appears to have several effects on NMDARs, including
a decrease in afﬁnity for the co-agonist glycine and a decrease in
the sensitivity of PKC-mediated NMDAR activation. Using dis-
sociated primary cultures of NAc neurons, it was shown that
these effects may be due, in part, to an increase in expression
or function of the NR2A subunit (Figure 1, postsynaptic GABA
neuron, Chronic condition; Martin et al., 2004). In vivo stud-
ies have reported increased protein levels of NR1 and NR2A in
the NAc after chronic morphine (Inoue et al., 2003; Murray et al.,
2007), although a separate study did not detect a change in NR2A
(Bajo et al., 2006). An intriguing possibility for how MORs and
NMDARs interact is described in the opioid pain literature. It
has been reported that MORs and NR1 subunits physically asso-
ciate in the periaqueductal gray (Rodriguez-Munoz et al., 2012).
Although it is not known if this occurs in the NAc or VTA, it
raises the possibility that MORs can have direct effects on gluta-
mate signaling through G protein signaling and/or through direct
interaction.
MOR–GLUTAMATE INTERACTIONS IN THE VTA
Both basal ﬁring rate and burst activity of VTA dopamine neu-
rons are increased after acute, and during chronic, morphine
treatment, resulting in elevated tonic levels of dopamine in the
NAc (Leri et al., 2003; Georges et al., 2006; although see Mazei-
Robison et al., 2011). However, an acute morphine challenge
fails to further increase dopamine neuron activity (Georges et al.,
2006), suggesting tolerance at the level of dopamine neuron
activation. Recently it has been shown that chronic morphine
increases intrinsic excitability of VTA dopamine neurons through
downregulation of K+ channels (Figure 2, Dopamine neuron,
Chronic condition) concomitantly with decreases in dopamine
soma size (Mazei-Robison et al., 2011). Thus, dopamine neu-
rons are more likely to ﬁre, but because of their smaller size
they release less dopamine. Taken together, these data raise the
possibility that not only does chronic morphine maintain its
inhibitory inﬂuence on GABAergic neurons in the VTA and
RMTg, but it also increases the sensitivity of dopamine neu-
rons to excitation (via Ih). Chronic morphine increases total
levels of GluR1 and NMDA NR1 subunits in the VTA (Fitzger-
ald et al., 1996), and ultrastructural analysis showed that surface
GluR1 is increased in dopaminergic and non-dopaminergic neu-
rons of the parabrachial and paranigral VTA (Figure 2, Dopamine
neuron, Chronic condition; Lane et al., 2008). These ﬁndings
could explain, at least in part, how postsynaptic glutamate trans-
mission is augmented with chronic opioid treatment, and they
also demonstrate that normal glutamatergic signaling is fun-
damentally altered. In the presence of morphine, arachidonic
acid-dependent activation of voltage-dependent K+ conductances
continues to reduce glutamate release from afferent terminals
(Manzoni and Williams, 1999). Yet signaling through GluR1
and possibly NR1 subunits on postsynaptic cells is enhanced
(LTP-like; Fitzgerald et al., 1996; Lane et al., 2008), with no
evidence so far of changes in other AMPAR or NMDAR sub-
units.
The effects of these seemingly opposite phenomenaonbehavior
are not well understood, and provide an important area of future
investigation. Given that AMPARs lacking GluR2 subunits and
NMDARs are able to pass Ca2+, the increase in VTA GluR1 and
NR1 likely results in increased Ca2+-mediated signaling (Figure 2,
Dopamine neuron, Chronic condition), which would be expected
to selectively strengthen those synaptic connections that express
elevated GluR1 and NR1. Consistent with this, intra-VTA infusion
of NMDAR or AMPAR antagonists prior to morphine condi-
tioning sessions or prior to tests for morphine conditioned place
preferences blocked the development and expression, respectively,
of place preferences (Popik and Kolasiewicz, 1999; Harris et al.,
2004). These effects appear to be limited to the rostral VTA
(enriched for dopamine neurons), as AMPAR blockade of the cau-
dal VTA (enriched for GABA neurons) had no effect on morphine
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conditioned place preferences (Shabat-Simon et al., 2008). Also,
mice with a global knockout of GluR1 show reduced naloxone-
precipitated withdrawal signs after an escalating dose regimen of
morphine (Vekovischeva et al., 2001). This suggests that GluR1 is
required for full dependence to develop. Consistent with the idea
that increased GluR1 expression in the VTA facilitates dopamine
neuron activation, it was shown that transient over-expression of
GluR1 usingHSV (herpes simplex virus) vectors in the rostralVTA
increased the rewarding effects of a morphine challenge, whereas
GluR overexpression in the caudal VTA had the opposite effect
(Carlezon et al., 2000).
OPIOID WITHDRAWAL
CLINICAL DESCRIPTION
With severe OUD, episodes of opioid withdrawal are more fre-
quent andmore aversive, and getting high gives only brief pleasure,
mostly attributed to cessation of withdrawal. Individuals now use
“to feel normal” and “to be able to function.” Pre-occupation with
obtaining a steady source of opioids is now prevalent, and episodes
of anxiety, irritability, and dysphoria are more frequent. This is a
stage of securing a steady opioid supply through friends, dealers,
or a doctor. This is also the stage when an individual who never
intended to use intravenously converts to injection use.
Forced abstinence is accompanied by severe withdrawal, anx-
iety, dysphoria, and intense, recurrent cravings to use opioids.
Those who cannot access a source become quite desperate to
obtain opioids, and will frequently self-injure in order to receive
opioid analgesia in emergency health care settings. The fear of
being cut off from opioid supply becomes ever-present and moti-
vation to hoard opioid supplies becomes habitual. This may
present as routinely exploring medicine cabinets while visiting
friends and family, and ﬁnding reasons to visit someone during
illness or post-surgical recovery, in hope of surreptitiously taking
narcotic analgesics from them. This may also be a time of criminal
behavior initiation (stealing, prostitution, running goods, etc.) to
support an opioid habit.
Withdrawal from chronic opioids essentially unmasks all the
neural adaptations thebrainproduced in its attempts to equilibrate
in the presence of drug. Consequently, neural circuits regulating
everything from gastrointestinal function to affective states are
instantly unbalanced, and an OWS emerges. A primary cause of
psychological withdrawal signs, which include anxiety, dysphoria,
depression, and irritability, is thought to be the dramatic reduc-
tion in dopamine neuron ﬁring and dopamine release in efferent
targets (Diana et al., 1995). Neural circuits other than the meso-
corticolimbic system also play critical roles in the OWS – both
somatic and psychological. These include norepinephrine (NE;
Weinshenker and Schroeder, 2007), corticotropin releasing factor
(CRF; Contarino and Papaleo, 2005), orexin (Mahler et al., 2012),
dynorphin (Yuferov et al., 2004; Schlosburg et al., 2013), and many
more (for review, see Koob, 2009). It is likely that MOR-induced
neuroplasticity in glutamate transmission underlies – at least in
part – the effects of each of these systems on OWS.
MOR–GLUTAMATE INTERACTIONS IN THE NAc
Spontaneous or naloxone-precipitated withdrawal from chronic
opioids leads to a general increase in neuronal activity and
transmitter release due to the removal of inhibitory MOR tone.
For example, GABA release is increased in the NAc during with-
drawal, particularly after activation of adenylate cyclase (Figure 1,
presynaptic GABA neuron, Withdrawal condition; Chieng and
Williams, 1998). Importantly, the ability of opioids to inhibit
GABA release is also enhanced, suggesting that this may be one
mechanism underlying the irresistible temptation to ﬁght OWS
with opioids themselves. Glutamate release has also been shown
to increase, and numerous studies have shown that systemic or
intracerebroventricular administration of NMDAR or AMPAR
antagonists reduces morphine tolerance and/or withdrawal signs
(Trujillo and Akil, 1991; Tokuyama et al., 1996; Gonzalez et al.,
1997). Much less is known about the speciﬁc role of NAc glu-
tamate transmission in the OWS. Extracellular glutamate levels
are signiﬁcantly increased in the NAc during morphine with-
drawal (Figure 1, presynaptic Glutamatergic neuron, Withdrawal
condition; Aghajanian et al., 1994; Desole et al., 1996; Sepul-
veda et al., 1998, 2004), although increased extracellular glutamate
does not necessarily mean that excitatory synaptic transmission
is increased (Kalivas, 2009). For example, it has been shown
that presynaptic mGluR2/3 inhibitory autoreceptor function is
increased during morphine withdrawal (Figure 1, presynaptic
Glutamatergic neuron, Withdrawal condition) and mGluR2/3
receptor agonists attenuate behavioral signs of morphine with-
drawal (Robbe et al., 2002b) and context-induced reinstatement
of heroin seeking (Bossert et al., 2006). These ﬁndings support
the idea that, although glutamate levels are increased, synap-
tic transmission may be decreased during withdrawal. Thus,
it is not yet clear how the combination of chronic morphine-
induced increases in AMPAR and NMDAR subunit expression,
withdrawal-induced increases in extracellular glutamate, and
increased autoinhibition of cortical afferents is synthesized into
behavioral output.
Understanding the molecular mechanisms by which increased
extracellular glutamate and AMPAR and NMDAR in the NAc
contribute to OWS will be key to understanding and prevent-
ing relapse. As one example, the mechanism by which presynaptic
mGluR2/3 receptor function is augmented is not known. Under
normal conditions, these Gαi-coupled receptors inhibit evoked
glutamate release by P/Q Ca2+ channel inhibition and PKA-
dependent mechanisms (Robbe et al., 2002a). Chronic morphine
and withdrawal has no effect on these processes in the NAc, rais-
ing the possibility of MOR-induced novel signaling mechanisms
(Robbe et al., 2002b). In a second example, Shen et al. (2011)
showed that 2 weeks of extinction following 2 weeks of daily
heroin self-administration resulted in thinner dendritic spines
in the NAc concomitant with an increase in surface expression
of NR2B subunits (Figure 1, postsynaptic GABA neuron, With-
drawal condition). Consequently, overall synaptic strength was
unchanged, but the AMPA/NMDA ratio (a proxy for synaptic
plasticity) was decreased due to increased NMDA current with
no change in AMPA current. What this means for the OWS was
not investigated in this study, but Shen et al. (2011) found that the
heroin withdrawal-induced increase in surface NR2B was neces-
sary for heroin- and cue-induced reinstatement of heroin seeking.
A heroin prime given to rats in which heroin seeking had been
extinguished resulted in a rapid increase in spine density and
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synaptic strength. This group concluded that increased NR2B
formed silent synapses in PFC to NAc core connections such that a
reinstatement trigger enabled synapses to rapidly develop an LTP-
like increase in ﬁeld-potential strength necessary for resumption
of heroin seeking. Based on prior studies of how silent synapses
are “unsilenced” it is likely that Ca2+-induced Ca2+/calmodulin-
dependent protein kinase II (CaMKII) facilitates shuttling of
AMPARs from extrasynaptic sites on the plasma membrane to
synaptic zones (Kerchner and Nicoll, 2008). In a different study,
NR2A knockout mice treated chronically with morphine show
reduced somatic withdrawal signs (Inoue et al., 2003). Restora-
tion of NR2A expression selectively in the NAc allowed for the
expression of somatic withdrawal signs. The NAc is not usu-
ally perceived as a substrate for somatic withdrawal, but this and
other studies (Harris and Aston-Jones, 1994; Chartoff et al., 2009)
indicate that it is a necessary – and perhaps even sufﬁcient –
component.
Morphine dependence andwithdrawalmay lower the threshold
for LTP-like processes through a cAMP mechanism. Acute stim-
ulation of Gαi-coupled MORs leads to a decrease in cAMP levels
(Childers, 1991). In the presence of chronic morphine, however,
molecular adaptations occur such that adenylate cyclase activ-
ity increases and cAMP levels return to approximately normal;
when morphine is discontinued or the opioid receptor antago-
nist naloxone is administered, cAMP levels dramatically increase
(for review, see Nestler and Aghajanian, 1997). Previously we have
shown that naloxone-precipitated withdrawal increases levels of
phosphorylated CREB (P-CREB) and P-GluR1Ser845 in the NAc of
morphine-dependent rats (Figure 3A; Chartoff et al., 2006). Using
primary cultures of dissociated striatal neurons, we demonstrated
that administration of naloxone to cultures treated chronically
with morphine enabled the dopamine D1 receptor agonist SKF
82958 to super-induce P-GluR1Ser845, an effect blocked by the
selective PKA inhibitor, H89 (Figure 3B). Together, these data
predict that surface expression (although not necessarily synap-
tic expression) of GluR1 subunits would increase during opioid
withdrawal. This has not been directly tested, although it has
been shown that targeted overexpression of GluR1 (but not
GluR2) in the NAc produces anhedonia in the intracranial self-
stimulation paradigm (Todtenkopf et al., 2006). One caveat may
be that withdrawal-induced increases in extracellular glutamate
trigger internalization/desensitization of AMPARs – reminiscent
of synaptic scaling (Turrigiano, 2008). These predictions are
not mutually exclusive, as glutamate-triggered desensitization
would likely be a pan-NAc effect whereas PKA-mediated P-
GluR1Ser845 and membrane insertion would likely occur only in
MOR-expressing neurons.
As discussed in the beginning of this review, acute and pro-
tracted OWS has been shown clinically to precipitate relapse.
Using an animal model of relapse, several studies have shown
that glutamate release and AMPAR activation in the NAc core
are necessary for reinstatement of heroin seeking after a period
of withdrawal in which operant responding for heroin is extin-
guished (Bossert et al., 2006, 2011, 2012; LaLumiere and Kalivas,
2008). These studies raise an important issue – namely whether
a heroin prime or a heroin-associated context (used as trig-
gers for reinstatement) produces a negative affective state akin
to OWS or a drug-like rewarding state that drives reinstate-
ment. Increasing evidence supports the former: activation of
NAc neurons (i.e., via glutamatergic transmission) is associated
with aversive states (Carlezon and Thomas, 2009). The relevance
of this hypothesis to heroin reinstatement studies remains to be
tested.
MOR–GLUTAMATE INTERACTIONS IN THE VTA
During morphine withdrawal GABA release is increased due
to MOR-induced upregulation of cAMP signaling (Figure 2,
GABAergic neuron, Withdrawal condition; Bonci and Williams,
1996, 1997), and glutamate release is decreased due to an increase
in thepotencyof GABAB receptor andmGluR-mediatedpresynap-
tic inhibition (Figure 2, Glutamate neuron,Withdrawal condition;
Manzoni and Williams, 1999). Combined, these effects lead to a
strong suppression of dopamine neuron activation (Diana et al.,
1995). Interestingly, it has been found that chronic morphine’s
almost ubiquitous upregulation of adenylate cyclase does not play
a role in modulation of glutamate release in the VTA during
withdrawal (Manzoni and Williams, 1999) leaving the mecha-
nism for augmented inhibition of glutamate release unknown
for now.
One confusing aspect of MOR–glutamate interactions in the
VTA during opioid withdrawal is that the actual time course of
withdrawal-induced effects on glutamatergic neurotransmission is
not known. Putting together available data, the immediate effect of
withdrawal is relief of MOR-mediated inhibition of glutamatergic
and GABAergic afferents to dopamine neurons and an increase
in glutamate and GABA release. Subsequently, glutamate and
GABA engage the more slowly acting metabotropic mGluR2/3
and GABAB receptors on glutamatergic terminals resulting in
decreased glutamatergic synaptic transmission (Figure 2, Glu-
tamate neuron, Withdrawal condition). The complexity of this
scenario raises the possibility that plasticity within micro-regions
containing MOR-expressing GABA and glutamate terminals that
synapse onto dopamine neurons results in ﬁne temporal and
spatial control over synaptic communication. How this affects
NMDAR and AMPAR function is not known, although one
prediction is thatAMPARs get promoted to synapseswithinmicro-
regions in which glutamate release is decreased and removed from
synapses in which glutamate release is increased. This selective
strengthening of synapses could provide a mechanism for associa-




In humans, the risk for relapse decreases the longer a person
remains abstinent. This is thought to be due, in part, to the fact that
the most powerful motivation to relapse stems from the desire to
alleviate the initial physiological withdrawal. Opioid agonist ther-
apies are extremely successful in treating this phase of the OWS.
Unfortunately, withdrawal from these medications also produces
withdrawal signs that can trigger relapse. Furthermore, they do
not treat other facets of abstinence, including cue reactivity.
Abstinent addicts are at high risk for relapse due to conditioned
craving and withdrawal elicited by previously drug-paired cues
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(Wikler, 1973; O’Brien et al., 1986). In fact, heroin addicts report
that the temptation or urge to use drug is elicited most powerfully
by drug-paired cues (Heather et al., 1991). Incentive salience is
the term that describes the unconscious and hypervigilant focus
on rapid identiﬁcation of any environmental cues that predict
access to opioid using. During early recovery treatment, patients
are taught to avoid high-risk “people, places, and things” to pre-
vent cue-conditioned relapse. However, they are often bafﬂed by
their inability to reliably detect and avoid such triggers. This is
because incentive salience is not a learned association within con-
scious awareness. A common clinical example would be that of an
abstinent opioid addict being drawn to a person who is actively
using while not recognizing that behavioral cues associated with
that person’s drug use, and not his/her personality, are the source
of interpersonal interest. On a positive note, cue reactivity wanes
with time, and it appears as if the success of abstinence itself begins
to provide a protective factor against relapse (see Epstein et al.,
2006).
MORPHINE–GLUTAMATE INTERACTIONS IN THE NAc
The majority of studies examining the role of NAc glutamater-
gic transmission in animal models of opioid relapse utilize the
reinstatement model of drug seeking, in which the operant
behavior producing contingent opioid administration is extin-
guished over time and then reinstated with non-contingent drug,
cue, or stress presentation (Shalev et al., 2002). There is lit-
tle data on how glutamatergic transmission regulates negative
reinforcement mechanisms stemming from OWS. In a seminal
study, LaLumiere and Kalivas (2008) demonstrated in rats that a
non-contingent heroin prime or discrete cues previously paired
with heroin infusions increased extracellular glutamate in the
NAc core via increased synaptic transmission from PFC affer-
ents. Intra-NAc core AMPAR blockade prevented reinstatement
of heroin seeking. A separate study showed that microinjec-
tions of the mGluR2/3 receptor agonist LY379268 into the NAc
shell, which inhibits evoked glutamate release from cortical affer-
ents, reduced context-induced reinstatement of heroin seeking
(Bossert et al., 2006). Interestingly, this group proposed that the
reduction in heroin seeking was due to decreases in the motiva-
tional signiﬁcance of the heroin context rather than to interference
with memory retrieval. This is consistent with the idea that incen-
tive salience underlies the power of a drug-paired cue to evoke
drug-seeking behavior, and raises the possibility that heroin-
associated cues increase synaptic glutamate release in the NAc
thus producing an aversive state (Carlezon and Thomas, 2009;
although see Stewart et al., 1984). Finally, chronic heroin self-
administration increases NR2B subunits in the NAc (see Chronic
Opioids). This is necessary for a heroin prime-induced increase
in synaptic strength, dendritic spine enlargement, and reinstate-
ment of heroin seeking after a period of extinction (Shen et al.,
2011).
Although the VTA has been implicated in conditioned and
unconditioned reinforcing effects of opioids (Stewart et al., 1984),
and intra-VTAmicroinjections of themGluR2/3 agonist LY379268
partially alleviate context-induced reinstatement of heroin seek-
ing (Bossert et al., 2004), there is relatively little data on VTA
glutamatergic transmission and relapse.
IMPLICATIONS FOR MEDICATIONS DEVELOPMENT
Opioid dependence and withdrawal disrupts excitatory neuro-
transmission in reward-related brain circuits, which contributes
to negative affective states associated with OWS and to corrup-
tion of motivated behavior away from natural rewards toward
obtaining and taking drug. Efforts are underway to develop phar-
macotherapies that target these aspects of addiction, but there
has not been a major advancement in treatment options. Given
what is known about the effects of MOR activation on glutamater-
gic transmission within the mesolimbic dopamine system, some
ideas for targets emerge (see Figures 1 and 2).
• Extracellular glutamate levels are increased in NAc and VTA
during opioid withdrawal.
• NMDAR levels/function is increased in both the NAc andVTA
with chronic opioids.
• MOR-expressing neurons become hyperexcitable with opioid
withdrawal.
• GluR1 AMPAR subunits decrease in NAc and increase in VTA
with chronic opioids.
Some compounds that act on these targets and have shown
some promise in the treatment of addiction include:
• Topiramate/Lamotrigine – Used therapeutically as anticonvul-
sants and mood stabilizers. Mechanisms of action include
inhibition of voltage-gatedNa+ andCa2+ channels and activa-
tion of GABAA receptors (Rogawski and Loscher, 2004). May
also block GluR5-containing AMPARs. Showed some promise
as an adjunct during detoxiﬁcation in a small study (Zullino
et al., 2004).
• Lacosamide –Used therapeutically as an anticonvulsant. Mech-
anismof action is to enhance slow inactivation of voltage-gated
Na+ channels (Beyreuther et al., 2007). Reduces the reward-
related effects of cocaine at doses that do not impact motor
capacity (Beguin et al., 2012).
• Memantine – Used to treat cognitive decline in Alzheimer’s
patients. Primary mechanism of action is as a noncompet-
itive NMDAR antagonist. Reduced expression of naloxone-
precipitated physical withdrawal signs in heroin-dependent
patients (Bisaga et al., 2001).
None of these compounds have demonstrated remarkable
effects, indicating that speciﬁcally targeting glutamate transmis-
sion will not be a panacea for opioid addiction. Notably none have
been tested on protracted withdrawal signs such as anxiety and
depression or on conditioned withdrawal or craving.
CONCLUSION
Mu opioid receptor agonists such as morphine and heroin per-
turb the delicate balance of neurophysiological communication
maintained by endogenous opioid peptides in the brain. The fact
that a heroin “rush” or naloxone-precipitated withdrawal signs in
opiate-dependent individuals can be felt within seconds of intra-
venous injection is evidence that the onset and offset of MOR
activation can have rapid effects on cellular activity. The fact that
some people develop a loss of control over opiate intake such
that they engage in compulsive drug taking behaviors – despite
severe negative consequences – is evidence that activation of MOR-
coupled G proteins can have slower effects to alter neural circuits
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regulating motivated behavior. And the fact that drug-associated
cues or contexts trigger relapse at some point in almost all opiate
addicts trying to stay abstinent is evidence that activation of MOR-
coupled G proteins facilitates long-lasting synaptic plasticity that
maintains drug-related memories. As discussed in this review, this
constellation of MOR effects stems in a large part from crosstalk
between MOR-associated G protein signaling and glutamatergic
neurotransmission.
ACKNOWLEDGMENTS
Funded by the National Institute on Drug Abuse (NIDA) grants
DA023606 (to Elena H. Chartoff) and CTN: National Institute on
Drug Abuse U10DA15831 (to Hilary S. Connery).
REFERENCES
Aghajanian, G. K., Kogan, J. H., and Moghaddam, B. (1994). Opiate with-
drawal increases glutamate and aspartate efﬂux in the locus coeruleus: an in
vivo microdialysis study. Brain Res. 636, 126–130. doi: 10.1016/0006-8993(94)
90186-4
Alderson, H. L., Parkinson, J. A., Robbins, T. W., and Everitt, B. J. (2001). The
effects of excitotoxic lesions of the nucleus accumbens core or shell regions on
intravenous heroin self-administration in rats. Psychopharmacology (Berl.) 153,
455–463. doi: 10.1007/s002130000634
Anggono, V., and Huganir, R. L. (2012). Regulation of AMPA receptor traf-
ﬁcking and synaptic plasticity. Curr. Opin. Neurobiol. 22, 461–469. doi:
10.1016/j.conb.2011.12.006
Badiani, A., Belin, D., Epstein, D., Calu, D., and Shaham, Y. (2011). Opiate versus
psychostimulant addiction: the differences do matter. Nat. Rev. Neurosci. 12,
685–700. doi: 10.1038/nrn3104
Bailey, C. P., and Connor, M. (2005). Opioids: cellular mechanisms of tol-
erance and physical dependence. Curr. Opin. Pharmacol. 5, 60–68. doi:
10.1016/j.coph.2004.08.012
Bajo, M., Crawford, E. F., Roberto, M., Madamba, S. G., and Siggins, G. R.
(2006). Chronic morphine treatment alters expression of N-methyl-D-aspartate
receptor subunits in the extended amygdala. J. Neurosci. Res. 83, 532–537. doi:
10.1002/jnr.20756
Beattie, E. C., Carroll, R. C., Yu, X., Morishita, W., Yasuda, H., Von Zastrow, M.,
et al. (2000). Regulation of AMPA receptor endocytosis by a signaling mechanism
shared with LTD. Nat. Neurosci. 3, 1291–1300. doi: 10.1038/81823
Becerra, L., Breiter, H. C., Wise, R., Gonzalez, R. G., and Borsook, D. (2001).
Reward circuitry activation by noxious thermal stimuli. Neuron 32, 927–946. doi:
10.1016/S0896-6273(01)00533-5
Beguin, C., Potter, D. N., Carlezon, W. A. Jr., Stohr, T., and Cohen, B. M.
(2012). Effects of the anticonvulsant lacosamide compared to valproate and
lamotrigine on cocaine-enhanced reward in rats. Brain Res. 1479, 44–51. doi:
10.1016/j.brainres.2012.08.030
Berendse, H. W., Galis-De Graaf, Y., and Groenewegen, H. J. (1992). Topo-
graphical organization and relationship with ventral striatal compartments of
prefrontal corticostriatal projections in the rat. J. Comp. Neurol. 316, 314–347.
doi: 10.1002/cne.903160305
Berendse,H.W., andGroenewegen,H. J. (1990). Organization of the thalamostriatal
projections in the rat, with special emphasis on the ventral striatum. J. Comp.
Neurol. 299, 187–228. doi: 10.1002/cne.902990206
Berridge, K. C., and Robinson, T. E. (1998). What is the role of dopamine in reward:
hedonic impact, reward learning, or incentive salience? Brain Res. Brain Res. Rev.
28, 309–369. doi: 10.1016/S0165-0173(98)00019-8
Beyreuther, B. K., Freitag, J., Heers, C., Krebsfanger, N., Scharfenecker, U., and
Stohr, T. (2007). Lacosamide: a review of preclinical properties. CNS Drug Rev.
13, 21–42. doi: 10.1111/j.1527-3458.2007.00001.x
Bisaga, A., Comer, S. D., Ward, A. S., Popik, P., Kleber, H. D., and Fischman,
M. W. (2001). The NMDA antagonist memantine attenuates the expression of
opioid physical dependence in humans. Psychopharmacology (Berl.) 157, 1–10.
doi: 10.1007/s002130100739
Bonci, A., and Williams, J. T. (1996). A common mechanism mediates long-term
changes in synaptic transmission after chronic cocaine and morphine. Neuron 16,
631–639. doi: 10.1016/S0896-6273(00)80082-3
Bonci, A., and Williams, J. T. (1997). Increased probability of GABA release during
withdrawal from morphine. J. Neurosci. 17, 796–803.
Bossert, J. M., Gray, S. M., Lu, L., and Shaham, Y. (2006). Activation of group
II metabotropic glutamate receptors in the nucleus accumbens shell attenuates
context-induced relapse to heroin seeking. Neuropsychopharmacology 31, 2197–
2209. doi: 10.1038/sj.npp.1300977
Bossert, J. M., Liu, S. Y., Lu, L., and Shaham, Y. (2004). A role of ventral tegmental
area glutamate in contextual cue-induced relapse to heroin seeking. J. Neurosci.
24, 10726–10730. doi: 10.1523/JNEUROSCI.3207-04.2004
Bossert, J. M., Stern, A. L., Theberge, F. R., Cifani, C., Koya, E., Hope, B.
T., et al. (2011). Ventral medial prefrontal cortex neuronal ensembles mediate
context-induced relapse to heroin. Nat. Neurosci. 14, 420–422. doi: 10.1038/
nn.2758
Bossert, J. M., Stern,A. L., Theberge, F. R.,Marchant, N. J.,Wang,H. L.,Morales,M.,
et al. (2012). Role of projections from ventral medial prefrontal cortex to nucleus
accumbens shell in context-induced reinstatement of heroin seeking. J. Neurosci.
32, 4982–4991. doi: 10.1523/JNEUROSCI.0005-12.2012
Botreau, F., Paolone,G., and Stewart, J. (2006). d-Cycloserine facilitates extinction of
a cocaine-induced conditioned place preference. Behav. Brain Res. 172, 173–178.
doi: 10.1016/j.bbr.2006.05.012
Bourdy, R., and Barrot, M. (2012). A new control center for dopaminergic
systems: pulling the VTA by the tail. Trends Neurosci. 35, 681–690. doi:
10.1016/j.tins.2012.06.007
Bozarth, M. A. (1987). Neuroanatomical boundaries of the reward-relevant opiate-
receptor ﬁeld in the ventral tegmental area as mapped by the conditioned
place preference method in rats. Brain Res. 414, 77–84. doi: 10.1016/0006-
8993(87)91327-8
Bozarth, M. A., and Wise, R. A. (1981). Heroin reward is dependent on a
dopaminergic substrate. Life Sci. 29, 1881–1886. doi: 10.1016/0024-3205(81)
90519-1
Bozarth, M. A., and Wise, R. A. (1983). Neural substrates of opiate reinforcement.
Prog. Neuropsychopharmacol. Biol. Psychiatry 7, 569–575. doi: 10.1016/0278-
5846(83)90027-1
Brebner, K., Wong, T. P., Liu, L., Liu, Y., Campsall, P., Gray, S., et al. (2005). Nucleus
accumbens long-term depression and the expression of behavioral sensitization.
Science 310, 1340–1343. doi: 10.1126/science.1116894
Britt, M. D., and Wise, R. A. (1983). Ventral tegmental site of opiate reward: antag-
onism by a hydrophilic opiate receptor blocker. Brain Res. 258, 105–108. doi:
10.1016/0006-8993(83)91232-5
Broekkamp, C. L., Van Den Bogaard, J. H., Heijnen, H. J., Rops, R. H., Cools, A. R.,
andVan Rossum, J. M. (1976). Separation of inhibiting and stimulating effects of
morphine on self-stimulation behaviour by intracerebral microinjections. Eur. J.
Pharmacol. 36, 443–446. doi: 10.1016/0014-2999(76)90099-6
Brog, J. S., Salyapongse, A., Deutch, A. Y., and Zahm, D. S. (1993). The pat-
terns of afferent innervation of the core and shell in the “accumbens” part
of the rat ventral striatum: immunohistochemical detection of retrogradely
transported ﬂuoro-gold. J. Comp. Neurol. 338, 255–278. doi: 10.1002/cne.903
380209
Brown, M. T., Bellone, C., Mameli, M., Labouebe, G., Bocklisch, C., Bal-
land, B., et al. (2010). Drug-driven AMPA receptor redistribution mimicked by
selective dopamine neuron stimulation. PLoS ONE 5:e15870. doi: 10.1371/jour-
nal.pone.0015870
Burnashev, N., Monyer, H., Seeburg, P. H., and Sakmann, B. (1992). Divalent ion
permeability of AMPA receptor channels is dominated by the edited form of a
single subunit. Neuron 8, 189–198. doi: 10.1016/0896-6273(92)90120-3
Carelli, R. M. (2002). The nucleus accumbens and reward: neurophysiological
investigations in behaving animals. Behav. Cogn. Neurosci. Rev. 1, 281–296. doi:
10.1177/1534582302238338
Carlezon, W. A. Jr., Boundy, V. A., Haile, C. N., Lane, S. B., Kalb, R. G., Neve, R. L.,
et al. (1997). Sensitization to morphine induced by viral-mediated gene transfer.
Science 277, 812–814. doi: 10.1126/science.277.5327.812
Carlezon,W. A. Jr., Haile, C. N., Coppersmith, R., Hayashi, Y., Malinow, R., Neve, R.
L., et al. (2000). Distinct sites of opiate reward and aversion within the midbrain
identiﬁed using a herpes simplex virus vector expressing GluR1. J. Neurosci. 20,
RC62.
Carlezon,W.A. Jr., andNestler, E. J. (2002). Elevated levels of GluR1 in themidbrain:
a trigger for sensitization to drugs of abuse? Trends Neurosci. 25, 610–615. doi:
10.1016/S0166-2236(02)02289-0
www.frontiersin.org May 2014 | Volume 5 | Article 116 | 15
Chartoff and Connery MOR–glutamate crosstalk in mesolimbic system
Carlezon, W. A. Jr., and Thomas, M. J. (2009). Biological substrates of reward and
aversion: a nucleus accumbens activity hypothesis. Neuropharmacology 56(Suppl.
1), 122–132. doi: 10.1016/j.neuropharm.2008.06.075
Carlezon, W. A. Jr., and Wise, R. A. (1996a). Microinjections of phencyclidine
(PCP) and related drugs into nucleus accumbens shell potentiate medial fore-
brain bundle brain stimulation reward. Psychopharmacologia 128, 413–420. doi:
10.1007/s002130050151
Carlezon, W. A. Jr., and Wise, R. A. (1996b). Rewarding actions of phencyclidine
and related drugs in nucleus accumbens shell and frontal cortex. J. Neurosci. 16,
3112–3122.
Carr, D. B., and Sesack, S. R. (2000). Projections from the rat prefrontal cortex
to the ventral tegmental area: target speciﬁcity in the synaptic associations with
mesoaccumbens and mesocortical neurons. J. Neurosci. 20, 3864–3873.
Chartoff, E. H., Barhight, M. F., Mague, S. D., Sawyer, A. M., and Carlezon, W. A.
Jr. (2009). Anatomically dissociable effects of dopamine D1 receptor agonists on
reward and relief of withdrawal inmorphine-dependent rats. Psychopharmacology
(Berl.) 204, 227–239. doi: 10.1007/s00213-008-1454-7
Chartoff, E. H., Mague, S. D., Barhight, M. F., Smith, A. M., and Carlezon, W. A. Jr.
(2006). Behavioral and molecular effects of dopamine D1 receptor stimulation
during naloxone-precipitated morphine withdrawal. J. Neurosci. 26, 6450–6457.
doi: 10.1523/JNEUROSCI.0491-06.2006
Chartoff, E. H., Papadopoulou, M., Konradi, C., and Carlezon, W. A. Jr. (2003a).
Dopamine-dependent increases in phosphorylation of cAMP response element
binding protein (CREB) during precipitated morphine withdrawal in primary
cultures of rat striatum. J. Neurochem. 87, 107–118. doi: 10.1046/j.1471-
4159.2003.01992.x
Chartoff, E. H., Papadopoulou, M., Konradi, C., and Carlezon, W. A. Jr. (2003b).
Effects of naloxone-precipitated morphine withdrawal on glutamate-mediated
signaling in striatal neurons in vitro. Ann. N. Y. Acad. Sci. 1003, 368–371. doi:
10.1196/annals.1300.028
Chen, Q., and Reiner, A. (1996). Cellular distribution of the NMDA recep-
tor NR2A/2B subunits in the rat striatum. Brain Res. 743, 346–352. doi:
10.1016/S0006-8993(96)01098-0
Chen, Y., Mestek, A., Liu, J., and Yu, L. (1993). Molecular cloning of a rat kappa
opioid receptor reveals sequence similarities to the mu and delta opioid receptors.
Biochem. J. 295(Pt 3), 625–628.
Cherubini, E., Herrling, P. L., Lanfumey, L., and Stanzione, P. (1988). Excitatory
amino acids in synaptic excitation of rat striatal neurones in vitro. J. Physiol. 400,
677–690.
Chieng, B., and Williams, J. T. (1998). Increased opioid inhibition of GABA release
in nucleus accumbens during morphine withdrawal. J. Neurosci. 18, 7033–7039.
Childers, S. R. (1991). Opioid receptor-coupled second messenger systems. Life Sci.
48, 1991–2003. doi: 10.1016/0024-3205(91)90154-4
Citri, A., and Malenka, R. C. (2008). Synaptic plasticity: multiple forms,
functions, and mechanisms. Neuropsychopharmacology 33, 18–41. doi:
10.1038/sj.npp.1301559
Clem, R. L., and Barth, A. (2006). Pathway-speciﬁc trafﬁcking of native AMPARs by
in vivo experience. Neuron 49, 663–670. doi: 10.1016/j.neuron.2006.01.019
Contarino, A., and Papaleo, F. (2005). The corticotropin-releasing factor receptor-1
pathway mediates the negative affective states of opiate withdrawal. Proc. Natl.
Acad. Sci. U.S.A. 102, 18649–18654. doi: 10.1073/pnas.0506999102
David, V., and Cazala, P. (2000). Anatomical and pharmacological speciﬁcity
of the rewarding effect elicited by microinjections of morphine into the
nucleus accumbens of mice. Psychopharmacology (Berl.) 150, 24–34. doi:
10.1007/s002130000425
Denier, N., Gerber, H., Vogel, M., Klarhofer, M., Riecher-Rossler, A., Wiesbeck,
G. A., et al. (2013). Reduction in cerebral perfusion after heroin adminis-
tration: a resting state arterial spin labeling study. PLoS ONE 8:e71461. doi:
10.1371/journal.pone.0071461
Desole, M. S., Esposito, G., Fresu, L., Migheli, R., Enrico, P., Mura, M. A., et al.
(1996). Effects of morphine treatment and withdrawal on striatal and limbic
monoaminergic activity and ascorbic acid oxidation in the rat. Brain Res. 723,
154–161. doi: 10.1016/0006-8993(96)00235-1
Devine, D. P., and Wise, R. A. (1994). Self-administration of morphine, DAMGO,
and DPDPE into the ventral tegmental area of rats. J. Neurosci. 14, 1978–1984.
Diana, M., Pistis, M., Muntoni, A., and Gessa, G. (1995). Profound decrease
of mesolimbic dopaminergic neuronal activity in morphine withdrawn rats. J.
Pharmacol. Exp. Ther. 272, 781–785.
Di Chiara, G., and Imperato, A. (1988a). Drugs abused by humans prefer-
entially increase synaptic dopamine concentrations in the mesolimbic system
of freely moving rats. Proc. Natl. Acad. Sci. U.S.A. 85, 5274–5278. doi:
10.1073/pnas.85.14.5274
Di Chiara, G., and Imperato, A. (1988b). Opposite effects of mu and kappa opiate
agonists on dopamine release in the nucleus accumbens and in the dorsal caudate
of freely moving rats. J. Pharmacol. Exp. Ther. 244, 1067–1080.
Dingledine, R., Borges, K., Bowie, D., and Traynelis, S. F. (1999). The glutamate
receptor ion channels. Pharmacol. Rev. 51, 7–61.
Dole, V. P., Nyswander, M. E., and Kreek, M. J. (1966). Narcotic blockade. Arch.
Intern. Med. 118, 304–309. doi: 10.1001/archinte.1966.00290160004002
Duman, R. S., Tallman, J. F., and Nestler, E. J. (1988). Acute and chronic opiate-
regulation of adenylate cyclase in brain: speciﬁc effects in locus coeruleus. J.
Pharmacol. Exp. Ther. 246, 1033–1039.
Dunah, A. W., Yasuda, R. P., Luo, J., Wang, Y., Prybylowski, K. L., and Wolfe, B.
B. (1999). Biochemical studies of the structure and function of the N-methyl-
D-aspartate subtype of glutamate receptors. Mol. Neurobiol. 19, 151–179. doi:
10.1007/BF02743658
Dworkin, S. I., Guerin, G. F., Goeders, N. E., and Smith, J. E. (1988).
Kainic acid lesions of the nucleus accumbens selectively attenuate morphine
self-administration. Pharmacol. Biochem. Behav. 29, 175–181. doi: 10.1016/0091-
3057(88)90292-4
Enrico, P., Mura, M. A., Esposito, G., Serra, P., Migheli, R., De Natale, G., et al.
(1998). Effect of naloxone on morphine-induced changes in striatal dopamine
metabolism and glutamate, ascorbic acid and uric acid release in freely moving
rats. Brain Res. 797, 94–102. doi: 10.1016/S0006-8993(98)00371-0
Epstein, D. H., Preston, K. L., Stewart, J., and Shaham, Y. (2006). Toward a model
of drug relapse: an assessment of the validity of the reinstatement procedure.
Psychopharmacology (Berl.) 189, 1–16. doi: 10.1007/s00213-006-0529-6
Esteban, J. A., Shi, S. H., Wilson, C., Nuriya, M., Huganir, R. L., and Malinow,
R. (2003). PKA phosphorylation of AMPA receptor subunits controls synap-
tic trafﬁcking underlying plasticity. Nat. Neurosci. 6, 136–143. doi: 10.1038/
nn997
Fields, H. L., Hjelmstad, G. O., Margolis, E. B., and Nicola, S. M. (2007). Ventral
tegmental area neurons in learned appetitive behavior and positive reinforce-
ment. Annu. Rev. Neurosci. 30, 289–316. doi: 10.1146/annurev.neuro.30.051606.
094341
Fitzgerald, L. W., Ortiz, J., Hamedani, A. G., and Nestler, E. J. (1996). Drugs of abuse
and stress increase the expression of GluR1 and NMDAR1 glutamate receptor
subunits in the rat ventral tegmental area: common adaptations among cross-
sensitizing agents. J. Neurosci. 16, 274–282.
Floresco, S. B., West, A. R., Ash, B., Moore, H., and Grace, A. A. (2003). Afferent
modulation of dopamine neuron ﬁring differentially regulates tonic and phasic
dopamine transmission. Nat. Neurosci. 6, 968–973. doi: 10.1038/nn1103
Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K.,
et al. (2003). Ofﬁce-based treatment of opiate addiction with a sublingual-tablet
formulation of buprenorphine and naloxone. N. Engl. J. Med. 349, 949–958. doi:
10.1056/NEJMoa022164
Garzon, M., and Pickel, V. M. (2001). Plasmalemmal mu-opioid receptor distri-
bution mainly in nondopaminergic neurons in the rat ventral tegmental area.
Synapse 41, 311–328. doi: 10.1002/syn.1088
Georges, F., Le Moine, C., and Aston-Jones, G. (2006). No effect of morphine on
ventral tegmental dopamine neurons during withdrawal. J. Neurosci. 26, 5720–
5726. doi: 10.1523/JNEUROSCI.5032-05.2006
Georges, F., Stinus, L., Bloch, B., and Le Moine, C. (1999). Chronic morphine expo-
sure and spontaneous withdrawal are associated with modiﬁcations of dopamine
receptor and neuropeptide gene expression in the rat striatum. Eur. J. Neurosci.
11, 481–490. doi: 10.1046/j.1460-9568.1999.00462.x
Gerfen, C. R. (1992). The neostriatal mosaic: multiple levels of compartmental
organization. Trends Neurosci. 15, 133–139. doi: 10.1016/0166-2236(92)90355-C
Gerfen, C. R., Engber, T. M., Mahan, L. C., Susel, Z., Chase, T. N., Monsma,
F. J., et al. (1990). D1 and D2 dopamine receptor-regulated gene expres-
sion of striatonigral and striatopallidal neurons. Science 250, 1429–1432. doi:
10.1126/science.2147780
Gerrits, M. A., and Van Ree, J. M. (1996). Effect of nucleus accumbens dopamine
depletion on motivational aspects involved in initiation of cocaine and heroin
self-administration in rats. Brain Res. 713, 114–124. doi: 10.1016/0006-
8993(95)01491-8
Frontiers in Pharmacology | Neuropharmacology May 2014 | Volume 5 | Article 116 | 16
Chartoff and Connery MOR–glutamate crosstalk in mesolimbic system
Giacchino, J. L., and Henriksen, S. J. (1996). Systemic morphine and local opioid
effects on neuronal activity in the medial prefrontal cortex. Neuroscience 70,
941–949. doi: 10.1016/0306-4522(95)00409-2
Glass, M. J., Lane, D. A., Colago, E. E., Chan, J., Schlussman, S. D., Zhou, Y.,
et al. (2008). Chronic administration of morphine is associated with a decrease
in surface AMPA GluR1 receptor subunit in dopamine D1 receptor expressing
neurons in the shell and non-D1 receptor expressing neurons in the core of the
rat nucleus accumbens. Exp. Neurol. 210, 750–761. doi: 10.1016/j.expneurol.2008.
01.012
Glass, M. J., Vanyo, L., Quimson, L., and Pickel, V. M. (2009). Ultrastructural rela-
tionship between N-methyl-D-aspartate-NR1 receptor subunit and mu-opioid
receptor in themouse central nucleus of the amygdala. Neuroscience 163, 857–867.
doi: 10.1016/j.neuroscience.2009.07.020
Goeders,N. E., Lane, J.D., andSmith, J. E. (1984). Self-administrationof methionine
enkephalin into the nucleus accumbens. Pharmacol. Biochem. Behav. 20, 451–455.
doi: 10.1016/0091-3057(84)90284-3
Gonzalez, P., Cabello, P., Germany,A., Norris, B., and Contreras, E. (1997). Decrease
of tolerance to, and physical dependence on morphine by, glutamate recep-
tor antagonists. Eur. J. Pharmacol. 332, 257–262. doi: 10.1016/S0014-2999(97)
01099-6
Grace, A. A., Floresco, S. B., Goto, Y., and Lodge, D. J. (2007). Regulation of ﬁring of
dopaminergic neurons and control of goal-directed behaviors. Trends Neurosci.
30, 220–227. doi: 10.1016/j.tins.2007.03.003
Gracy, K. N., Svingos, A. L., and Pickel, V. M. (1997). Dual ultrastructural localiza-
tion of mu-opioid receptors and NMDA-type glutamate receptors in the shell of
the rat nucleus accumbens. J. Neurosci. 17, 4839–4848.
Groenewegen, H. J., Vermeulen-Van Der Zee, E., Te Kortschot, A., and Wit-
ter, M. P. (1987). Organization of the projections from the subiculum to the
ventral striatum in the rat. A study using anterograde transport of Phaseolus
vulgaris leucoagglutinin. Neuroscience 23, 103–120. doi: 10.1016/0306-4522(87)
90275-2
Gysling, K., andWang, R. Y. (1983). Morphine-induced activation of A10 dopamine
neurons in the rat. Brain Res. 277, 119–127. doi: 10.1016/0006-8993(83)90913-7
Haber, S. N., Fudge, J. L., and Mcfarland, N. R. (2000). Striatonigrostriatal pathways
in primates form an ascending spiral from the shell to the dorsolateral striatum.
J. Neurosci. 20, 2369–2382.
Haber, S. N., and Knutson, B. (2010). The reward circuit: linking pri-
mate anatomy and human imaging. Neuropsychopharmacology 35, 4–26. doi:
10.1038/npp.2009.129
Haber, S. N., Lynd, E., Klein, C., and Groenewegen, H. J. (1990). Topo-
graphic organization of the ventral striatal efferent projections in the rhesus
monkey: an anterograde tracing study. J. Comp. Neurol. 293, 282–298. doi:
10.1002/cne.902930210
Harris, G. C., andAston-Jones, G. (1994). Involvement of D2 dopamine receptors in
the nucleus accumbens in the opiate withdrawal syndrome. Nature 371, 155–157.
doi: 10.1038/371155a0
Harris, G. C., Wimmer, M., Byrne, R., and Aston-Jones, G. (2004). Glutamate-
associated plasticity in the ventral tegmental area is necessary for condition-
ing environmental stimuli with morphine. Neuroscience 129, 841–847. doi:
10.1016/j.neuroscience.2004.09.018
Heather, N., Stallard, A., and Tebbutt, J. (1991). Importance of substance cues in
relapse among heroin users: comparison of two methods of investigation. Addict.
Behav. 16, 41–49. doi: 10.1016/0306-4603(91)90038-J
Heine, M., Groc, L., Frischknecht, R., Beique, J. C., Lounis, B., Rumbaugh, G., et al.
(2008). Surface mobility of postsynaptic AMPARs tunes synaptic transmission.
Science 320, 201–205. doi: 10.1126/science.1152089
Herrold, A. A., Persons, A. L., and Napier, T. C. (2013). Cellular distribution of
AMPA receptor subunits and mGlu5 following acute and repeated adminis-
tration of morphine or methamphetamine. J. Neurochem. 126, 503–517. doi:
10.1111/jnc.12323
Hokfelt, T., Broberger, C., Xu, Z. Q., Sergeyev, V., Ubink, R., and Diez, M.
(2000). Neuropeptides – an overview. Neuropharmacology 39, 1337–1356. doi:
10.1016/S0028-3908(00)00010-1
Hollmann, M., Hartley, M., and Heinemann, S. (1991). Ca2+ permeability of KA-
AMPA – gated glutamate receptor channels depends on subunit composition.
Science 252, 851–853. doi: 10.1126/science.1709304
Hollmann, M., and Heinemann, S. (1994). Cloned glutamate receptors. Annu. Rev.
Neurosci. 17, 31–108. doi: 10.1146/annurev.ne.17.030194.000335
Hu, X. T., and White, F. J. (1996). Glutamate receptor regulation of rat nucleus
accumbens neurons in vivo. Synapse 23, 208–218. doi: 10.1002/(SICI)1098-
2396(199607)23:3<208::AID-SYN10>3.0.CO;2-V
Hyman, S. E., Malenka, R. C., and Nestler, E. J. (2006). Neural mechanisms of
addiction: the role of reward-related learning and memory. Annu. Rev. Neurosci.
29, 565–598. doi: 10.1146/annurev.neuro.29.051605.113009
Ikemoto, S. (2007). Dopamine reward circuitry: two projection systems from the
ventral midbrain to the nucleus accumbens-olfactory tubercle complex. Brain
Res. Rev. 56, 27–78. doi: 10.1016/j.brainresrev.2007.05.004
Ikemoto, S., and Panksepp, J. (1999). The role of nucleus accumbens dopamine in
motivated behavior: a unifying interpretation with special reference to reward-
seeking. Brain Res. Brain Res. Rev. 31, 6–41. doi: 10.1016/S0165-0173(99)
00023-5
Inoue, M., Mishina, M., and Ueda, H. (2003). Locus-speciﬁc rescue of GluRep-
silon1 NMDA receptors in mutant mice identiﬁes the brain regions important
for morphine tolerance and dependence. J. Neurosci. 23, 6529–6536.
Jacobs, E. H., Wardeh, G., Smit, A. B., and Schoffelmeer, A. N. (2005). Mor-
phine causes a delayed increase in glutamate receptor functioning in the nucleus
accumbens core. Eur. J. Pharmacol. 511, 27–30. doi: 10.1016/j.ejphar.2005.
02.009
Jalabert, M., Bourdy, R., Courtin, J., Veinante, P., Manzoni, O. J., Barrot,
M., et al. (2011). Neuronal circuits underlying acute morphine action on
dopamine neurons. Proc. Natl. Acad. Sci. U.S.A. 108, 16446–16450. doi:
10.1073/pnas.1105418108
Jensen, J., Mcintosh, A. R., Crawley, A. P., Mikulis, D. J., Remington, G.,
and Kapur, S. (2003). Direct activation of the ventral striatum in anticipa-
tion of aversive stimuli. Neuron 40, 1251–1257. doi: 10.1016/S0896-6273(03)
00724-4
Jhou, T. C., Geisler, S., Marinelli, M., Degarmo, B. A., and Zahm, D. S. (2009). The
mesopontine rostromedial tegmental nucleus: a structure targeted by the lateral
habenula that projects to the ventral tegmental area of Tsai and substantia nigra
compacta. J. Comp. Neurol. 513, 566–596. doi: 10.1002/cne.21891
Johnson, S. W., and North, R. A. (1992). Opioids excite dopamine neurons by
hyperpolarization of local interneurons. J. Neurosci. 12, 483–488.
Johnston, L. D., O’Malley, P. M., Miech, R. A., Bachman, J. G., and Schulenberg, J. E.
(2014). Monitoring the FutureNational Survey Results onDrugUse: 2013Overview,
Key Findings on Adolescent Drug Use. Ann Arbor: University of Michigan.
Ju, W., Morishita, W., Tsui, J., Gaietta, G., Deerinck, T. J., Adams, S. R., et al. (2004).
Activity-dependent regulation of dendritic synthesis and trafﬁcking of AMPA
receptors. Nat. Neurosci. 7, 244–253. doi: 10.1038/nn1189
Kalivas, P. W. (2009). The glutamate homeostasis hypothesis of addiction. Nat. Rev.
Neurosci. 10, 561–572. doi: 10.1038/nrn2515
Kalivas, P. W., Lalumiere, R. T., Knackstedt, L., and Shen, H. (2009). Gluta-
mate transmission in addiction. Neuropharmacology 56(Suppl. 1), 169–173. doi:
10.1016/j.neuropharm.2008.07.011
Kauer, J. A., and Malenka, R. C. (2007). Synaptic plasticity and addiction. Nat. Rev.
Neurosci. 8, 844–858. doi: 10.1038/nrn2234
Kawaguchi, Y., Wilson, C. J., Augood, S. J., and Emson, P. C. (1995). Stri-
atal interneurones: chemical, physiological and morphological characterization.
Trends Neurosci. 18, 527–535. doi: 10.1016/0166-2236(95)98374-8
Kelley, A. E., and Domesick, V. B. (1982). The distribution of the projection from
the hippocampal formation to the nucleus accumbens in the rat: an anterograde-
and retrograde-horseradish peroxidase study. Neuroscience 7, 2321–2335. doi:
10.1016/0306-4522(82)90198-1
Kelley, A. E., Domesick, V. B., and Nauta, W. J. (1982). The amygdalostriatal pro-
jection in the rat – an anatomical study by anterograde and retrograde tracing
methods. Neuroscience 7, 615–630. doi: 10.1016/0306-4522(82)90067-7
Kerchner, G. A., and Nicoll, R. A. (2008). Silent synapses and the emergence
of a postsynaptic mechanism for LTP. Nat. Rev. Neurosci. 9, 813–825. doi:
10.1038/nrn2501
Kessels, H. W., and Malinow, R. (2009). Synaptic AMPA receptor plasticity and
behavior. Neuron 61, 340–350. doi: 10.1016/j.neuron.2009.01.015
Khan, Z. U., Gutierrez, A., Martin, R., Penaﬁel, A., Rivera, A., and De La Calle,
A. (2000). Dopamine D5 receptors of rat and human brain. Neuroscience 100,
689–699. doi: 10.1016/S0306-4522(00)00274-8
Konradi, C., Cole, R. L., Heckers, S., and Hyman, S. E. (1994). Amphetamine reg-
ulates gene expression in rat striatum via transcription factor CREB. J. Neurosci.
14, 5623–5634.
www.frontiersin.org May 2014 | Volume 5 | Article 116 | 17
Chartoff and Connery MOR–glutamate crosstalk in mesolimbic system
Konradi, C., Leveque, J. C., and Hyman, S. E. (1996). Amphetamine and
dopamine-induced immediate early gene expression in striatal neurons depends
on postsynaptic NMDA receptors and calcium. J. Neurosci. 16, 4231–4239.
Koob, G. F. (1992). Drugs of abuse: anatomy, pharmacology and function of reward
pathways. Trends Pharmacol. Sci. 13, 177–184. doi: 10.1016/0165-6147(92)
90060-J
Koob, G. F. (2009). Neurobiological substrates for the dark side of com-
pulsivity in addiction. Neuropharmacology 56(Suppl. 1), 18–31. doi:
10.1016/j.neuropharm.2008.07.043
Koob, G. F., Maldonado, R., and Stinus, L. (1992). Neural substrates of opiate
withdrawal. Trends Neurosci. 15, 186–191. doi: 10.1016/0166-2236(92)90171-4
Kosel, M., Noss, R. S., Hammig, R., Wielepp, P., Bundeli, P., Heidbreder, R., et al.
(2008). Cerebral blood ﬂow effects of acute intravenous heroin administration.
Eur. Neuropsychopharmacol. 18, 278–285. doi: 10.1016/j.euroneuro.2007.11.007
Kreek, M. J., and Koob, G. F. (1998). Drug dependence: stress and dysregulation
of brain reward pathways. Drug Alcohol Depend. 51, 23–47. doi: 10.1016/S0376-
8716(98)00064-7
Kuppenbender, K. D., Standaert, D. G., Feuerstein, T. J., Penney, J. B. Jr., Young,
A. B., and Landwehrmeyer, G. B. (2000). Expression of NMDA receptor sub-
unit mRNAs in neurochemically identiﬁed projection and interneurons in the
human striatum. J. Comp. Neurol. 419, 407–421. doi: 10.1002/(SICI)1096-
9861(20000417)419:4<407::AID-CNE1>3.0.CO;2-I
LaLumiere, R. T., and Kalivas, P. W. (2008). Glutamate release in the nucleus
accumbens core is necessary for heroin seeking. J. Neurosci. 28, 3170–3177. doi:
10.1523/JNEUROSCI.5129-07.2008
Lane, D. A., Lessard, A. A., Chan, J., Colago, E. E., Zhou, Y., Schlussman,
S. D., et al. (2008). Region-speciﬁc changes in the subcellular distribution
of AMPA receptor GluR1 subunit in the rat ventral tegmental area after
acute or chronic morphine administration. J. Neurosci. 28, 9670–9681. doi:
10.1523/JNEUROSCI.2151-08.2008
Law, P.Y.,Wong,Y.H., and Loh,H.H. (2000). Molecularmechanisms and regulation
of opioid receptor signaling. Annu. Rev. Pharmacol. Toxicol. 40, 389–430. doi:
10.1146/annurev.pharmtox.40.1.389
Le Merrer, J., Becker, J. A., Befort, K., and Kieffer, B. L. (2009). Reward pro-
cessing by the opioid system in the brain. Physiol. Rev. 89, 1379–1412. doi:
10.1152/physrev.00005.2009
Leri, F., Flores, J., Rajabi, H., and Stewart, J. (2003). Effects of cocaine in rats
exposed to heroin. Neuropsychopharmacology 28, 2102–2116. doi: 10.1038/sj.npp.
1300284
Li, S. X., Shi, J., Epstein, D. H., Wang, X., Zhang, X. L., Bao, Y. P., et al. (2009).
Circadian alteration in neurobiology during 30 days of abstinence in heroin users.
Biol. Psychiatry 65, 905–912. doi:10.1016/j.biopsych.2008.11.025
Liu, S. Q., and Cull-Candy, S. G. (2000). Synaptic activity at calcium-permeable
AMPA receptors induces a switch in receptor subtype. Nature 405, 454–458. doi:
10.1038/35013064
Lobo, M. K. (2009). Molecular proﬁling of striatonigral and striatopallidal medium
spiny neurons past, present, and future. Int. Rev. Neurobiol. 89, 1–35. doi:
10.1016/S0074-7742(09)89001-6
Lodge, D. J., and Grace, A. A. (2006). The laterodorsal tegmentum is essential for
burst ﬁring of ventral tegmental area dopamine neurons. Proc. Natl. Acad. Sci.
U.S.A. 103, 5167–5172. doi: 10.1073/pnas.0510715103
London, E. D., Broussolle, E. P., Links, J. M., Wong, D. F., Cascella, N. G., Dan-
nals, R. F., et al. (1990). Morphine-induced metabolic changes in human brain.
Studies with positron emission tomography and [ﬂuorine 18]ﬂuorodeoxyglu-
cose. Arch. Gen. Psychiatry 47, 73–81. doi: 10.1001/archpsyc.1990.018101300
75010
Lu, X. Y., Ghasemzadeh, M. B., and Kalivas, P. W. (1998). Expression of D1
receptor, D2 receptor, substance P and enkephalin messenger RNAs in the neu-
rons projecting from the nucleus accumbens. Neuroscience 82, 767–780. doi:
10.1016/S0306-4522(97)00327-8
Luscher, C. (2013). Cocaine-evoked synaptic plasticity of excitatory transmission
in the ventral tegmental area. Cold Spring Harb. Perspect. Med. 3, a012013. doi:
10.1101/cshperspect.a012013
Magura, S., and Rosenblum, A. (2001). Leaving methadone treatment: lessons
learned, lessons forgotten, lessons ignored. Mt. Sinai J. Med. 68, 62–74.
Mahler, S.V., Smith, R. J.,Moorman,D. E., Sartor, G. C., andAston-Jones, G. (2012).
Multiple roles for orexin/hypocretin in addiction. Prog. Brain Res. 198, 79–121.
doi: 10.1016/B978-0-444-59489-1.00007-0
Malinow, R., and Malenka, R. C. (2002). AMPA receptor trafﬁck-
ing and synaptic plasticity. Annu. Rev. Neurosci. 25, 103–126. doi:
10.1146/annurev.neuro.25.112701.142758
Mangiavacchi, S., and Wolf, M. E. (2004). D1 dopamine receptor stimulation
increases the rate of AMPA receptor insertion onto the surface of cultured
nucleus accumbens neurons through a pathway dependent on protein kinase
A. J. Neurochem. 88, 1261–1271. doi: 10.1046/j.1471-4159.2003.02248.x
Mansour, A., Fox, C. A., Akil, H., and Watson, S. J. (1995a). Opioid-receptor
mRNA expression in the rat CNS: anatomical and functional implications. Trends
Neurosci. 18, 22–29. doi: 10.1016/0166-2236(95)93946-U
Mansour, A., Fox, C. A., Burke, S., Akil, H., and Watson, S. J. (1995b). Immunohis-
tochemical localization of the cloned mu opioid receptor in the rat CNS. J. Chem.
Neuroanat. 8, 283–305. doi: 10.1016/0891-0618(95)00055-C
Mansour, A., Fox, C. A., Thompson, R. C., Akil, H., and Watson, S. J. (1994). mu-
Opioid receptor mRNA expression in the rat CNS: comparison to mu-receptor
binding. Brain Res. 643, 245–265. doi: 10.1016/0006-8993(94)90031-0
Mansour, A., Khachaturian, H., Lewis, M. E., Akil, H., and Watson, S. J.
(1988). Anatomy of CNS opioid receptors. Trends Neurosci. 11, 308–314. doi:
10.1016/0166-2236(88)90093-8
Manzoni, O. J., and Williams, J. T. (1999). Presynaptic regulation of glutamate
release in the ventral tegmental area during morphine withdrawal. J. Neurosci. 19,
6629–6636.
Martin, G., Guadano-Ferraz, A., Morte, B., Ahmed, S., Koob, G. F., De Lecea, L.,
et al. (2004). Chronic morphine treatment alters N-methyl-D-aspartate receptors
in freshly isolated neurons from nucleus accumbens. J. Pharmacol. Exp. Ther. 311,
265–273. doi: 10.1124/jpet.104.067504
Martin, G., Nie, Z., and Siggins, G. R. (1997). mu-Opioid receptors modulate
NMDA receptor-mediated responses in nucleus accumbens neurons. J. Neurosci.
17, 11–22.
Martin, G., Przewlocki, R., and Siggins, G. R. (1999). Chronic morphine treatment
selectively augments metabotropic glutamate receptor-induced inhibition of N-
methyl-D-aspartate receptor-mediated neurotransmission in nucleus accumbens.
J. Pharmacol. Exp. Ther. 288, 30–35.
Martin, W. R., and Jasinski, D. R. (1969). Physiological parameters of morphine
dependence in man – tolerance, early abstinence, protracted abstinence. J.
Psychiatr. Res. 7, 9–17. doi: 10.1016/0022-3956(69)90007-7
Matthes, H. W., Maldonado, R., Simonin, F., Valverde, O., Slowe, S., Kitchen, I.,
et al. (1996). Loss of morphine-induced analgesia, reward effect and withdrawal
symptoms in mice lacking the mu-opioid-receptor gene. Nature 383, 819–823.
doi: 10.1038/383819a0
Mattick, R. P., Kimber, J., Breen, C., and Davoli, M. (2008). Buprenorphine
maintenance versus placebo or methadone maintenance for opioid depen-
dence. Cochrane Database Syst. Rev. CD002207. doi: 10.1002/14651858.CD0022
07.pub3
Mazei-Robison, M. S., Koo, J. W., Friedman, A. K., Lansink, C. S., Robison, A.
J., Vinish, M., et al. (2011). Role for mTOR signaling and neuronal activity
in morphine-induced adaptations in ventral tegmental area dopamine neurons.
Neuron 72, 977–990. doi: 10.1016/j.neuron.2011.10.012
McFarland, K., and Kalivas, P. W. (2001). The circuitry mediating cocaine-induced
reinstatement of drug-seeking behavior. J. Neurosci. 21, 8655–8663.
Mello, N. K., and Negus, S. S. (1996). Preclinical evaluation of pharmacothera-
pies for treatment of cocaine and opioid abuse using drug self-administration
procedures. Neuropsychopharmacology 14, 375–424. doi: 10.1016/0893-133X(95)
00274-H
Mickiewicz, A. L., and Napier, T. C. (2011). Repeated exposure to morphine alters
surface expression of AMPA receptors in the rat medial prefrontal cortex. Eur. J.
Neurosci. 33, 259–265. doi: 10.1111/j.1460-9568.2010.07502.x
Mink, J. W. (1996). The basal ganglia: focused selection and inhibition of
competing motor programs. Prog. Neurobiol. 50, 381–425. doi: 10.1016/S0301-
0082(96)00042-1
Mogenson, G. J., Jones, D. L., and Yim, C. Y. (1980). From motivation to action –
functional interface between the limbic system and the motor system. Prog.
Neurobiol. 14, 69–97. doi: 10.1016/0301-0082(80)90018-0
Monyer, H., Sprengel, R., Schoepfer, R., Herb, A., Higuchi, M., Lomeli, H., et al.
(1992). Heteromeric NMDA receptors: molecular and functional distinction of
subtypes. Science 256, 1217–1221. doi: 10.1126/science.256.5060.1217
Murray, F., Harrison, N. J., Grimwood, S., Bristow, L. J., and Hutson, P. H.
(2007). Nucleus accumbens NMDA receptor subunit expression and function
Frontiers in Pharmacology | Neuropharmacology May 2014 | Volume 5 | Article 116 | 18
Chartoff and Connery MOR–glutamate crosstalk in mesolimbic system
is enhanced in morphine-dependent rats. Eur. J. Pharmacol. 562, 191–197. doi:
10.1016/j.ejphar.2007.01.027
Myers, K. M., and Carlezon,W. A. Jr. (2010a). D-Cycloserine facilitates extinction of
naloxone-induced conditioned place aversion in morphine-dependent rats. Biol.
Psychiatry 67, 85–87. doi: 10.1016/j.biopsych.2009.08.015
Myers, K. M., and Carlezon, W. A. Jr. (2010b). Extinction of drug- and withdrawal-
paired cues in animal models: relevance to the treatment of addiction. Neurosci.
Biobehav. Rev. 35, 285–302. doi: 10.1016/j.neubiorev.2010.01.011
Nair-Roberts, R. G., Chatelain-Badie, S. D., Benson, E., White-Cooper, H., Bolam,
J. P., and Ungless, M. A. (2008). Stereological estimates of dopaminergic,
GABAergic and glutamatergic neurons in the ventral tegmental area, substan-
tia nigra and retrorubral ﬁeld in the rat. Neuroscience 152, 1024–1031. doi:
10.1016/j.neuroscience.2008.01.046
Nestler, E. J., andAghajanian,G. K. (1997). Molecular and cellular basis of addiction.
Science 278, 58–63. doi: 10.1126/science.278.5335.58
Nestler, E. J., and Tallman, J. F. (1988). Chronic morphine treatment increases
cyclic AMP-dependent protein kinase activity in the rat locus coeruleus. Mol.
Pharmacol. 33, 127–132.
Niehaus, J. L., Murali, M., and Kauer, J. A. (2010). Drugs of abuse and stress impair
LTP at inhibitory synapses in the ventral tegmental area. Eur. J. Neurosci. 32,
108–117. doi: 10.1111/j.1460-9568.2010.07256.x
NSDUH. (2013). Results from the 2012 National Survey on Drug Use and Health:
Summary of National Findings. Rockville: Substance Abuse and Mental Health
Services Administration.
O’Brien, C. P., Ehrman, R. N., and Ternes, J. W. (1986). “Classical conditioning in
human opioid dependence,” in Behavioral Analysis of Drug Dependence, ed. S.
Goldberg (Orlando: Academic Press), 329–356.
Olds,M. E. (1982). Reinforcing effects of morphine in the nucleus accumbens. Brain
Res. 237, 429–440. doi: 10.1016/0006-8993(82)90454-1
Paolone, G., Botreau, F., and Stewart, J. (2009). The facilitative effects of D-
cycloserine on extinction of a cocaine-induced conditioned place preference can
be long lasting and resistant to reinstatement. Psychopharmacology (Berl.) 202,
403–409. doi: 10.1007/s00213-008-1280-y
Pasternak, G. W. (2012). Preclinical pharmacology and opioid combinations. Pain
Med. 13(Suppl. 1), S4–S11. doi: 10.1111/j.1526-4637.2012.01335.x
Peoples, L. L., and West, M. O. (1996). Phasic ﬁring of single neurons in
the rat nucleus accumbens correlated with the timing of intravenous cocaine
self-administration. J. Neurosci. 16, 3459–3473.
Pettit, H. O., Ettenberg, A., Bloom, F. E., and Koob, G. F. (1984). Destruction
of dopamine in the nucleus accumbens selectively attenuates cocaine but not
heroin self-administration in rats. Psychopharmacology (Berl.) 84, 167–173. doi:
10.1007/BF00427441
Pierce, R. C., and Wolf, M. E. (2013). Psychostimulant-induced neu-
roadaptations in nucleus accumbens AMPA receptor transmission. Cold
Spring Harb. Perspect. Med. 3, a012021. doi: 10.1101/cshperspect.
a012021
Popik, P., and Kolasiewicz, W. (1999). Mesolimbic NMDA receptors are implicated
in the expression of conditioned morphine reward. Naunyn Schmiedebergs Arch.
Pharmacol. 359, 288–294. doi: 10.1007/PL00005354
Reimers, J. M., Milovanovic, M., and Wolf, M. E. (2011). Quantitative analysis of
AMPA receptor subunit composition in addiction-related brain regions. Brain
Res. 1367, 223–233. doi: 10.1016/j.brainres.2010.10.016
Reynolds, S. M., and Berridge, K. C. (2002). Positive and negative motivation in
nucleus accumbens shell: bivalent rostrocaudal gradients for GABA-elicited eat-
ing, taste “liking”/“disliking” reactions, place preference/avoidance, and fear. J.
Neurosci. 22, 7308–7320.
Robbe, D., Alonso, G., Chaumont, S., Bockaert, J., and Manzoni, O. J. (2002a).
Role of p/q-Ca2+ channels in metabotropic glutamate receptor 2/3-dependent
presynaptic long-term depression at nucleus accumbens synapses. J. Neurosci. 22,
4346–4356.
Robbe, D., Bockaert, J., and Manzoni, O. J. (2002b). Metabotropic glutamate
receptor 2/3-dependent long-term depression in the nucleus accumbens is
blocked in morphine withdrawn mice. Eur. J. Neurosci. 16, 2231–2235. doi:
10.1046/j.1460-9568.2002.02273.x
Rodriguez-Munoz, M., Sanchez-Blazquez, P., Vicente-Sanchez, A., Berrocoso, E.,
and Garzon, J. (2012). The mu-opioid receptor and the NMDA receptor associate
in PAG neurons: implications in pain control. Neuropsychopharmacology 37, 338–
349. doi: 10.1038/npp.2011.155
Rogawski, M. A., and Loscher, W. (2004). The neurobiology of antiepileptic drugs.
Nat. Rev. Neurosci. 5, 553–564. doi: 10.1038/nrn1430
Roitman, M. F., Wheeler, R. A., and Carelli, R. M. (2005). Nucleus accumbens
neurons are innately tuned for rewarding and aversive taste stimuli, encode
their predictors, and are linked to motor output. Neuron 45, 587–597. doi:
10.1016/j.neuron.2004.12.055
Rossetti, Z. L., Hmaidan, Y., and Gessa, G. L. (1992). Marked inhibition of
mesolimbic dopamine release: a common feature of ethanol, morphine, cocaine
and amphetamine abstinence in rats. Eur. J. Pharmacol. 221, 227–234. doi:
10.1016/0014-2999(92)90706-A
Rothwell, P. E., Thomas, M. J., and Gewirtz, J. C. (2012). Protracted manifesta-
tions of acute dependence after a single morphine exposure. Psychopharmacology
(Berl.) 219, 991–998. doi: 10.1007/s00213-011-2425-y
Saal, D., Dong, Y., Bonci, A., and Malenka, R. C. (2003). Drugs of abuse and stress
trigger a common synaptic adaptation in dopamine neurons. Neuron 37, 577–582.
doi: 10.1016/S0896-6273(03)00021-7
Salamone, J. D., and Correa, M. (2012). The mysterious motivational functions
of mesolimbic dopamine. Neuron 76, 470–485. doi: 10.1016/j.neuron.2012.
10.021
Schildein, S., Agmo, A., Huston, J. P., and Schwarting, R. K. (1998). Intraac-
cumbens injections of substance P, morphine and amphetamine: effects on
conditioned place preference and behavioral activity. Brain Res. 790, 185–194.
doi: 10.1016/S0006-8993(98)00062-6
Schilstrom, B., Yaka, R., Argilli, E., Suvarna, N., Schumann, J., Chen, B. T.,
et al. (2006). Cocaine enhances NMDA receptor-mediated currents in ven-
tral tegmental area cells via dopamine D5 receptor-dependent redistribution of
NMDA receptors. J. Neurosci. 26, 8549–8558. doi: 10.1523/JNEUROSCI.5179-
05.2006
Schlaepfer, T. E., Strain, E. C., Greenberg, B. D., Preston, K. L., Lancaster, E.,
Bigelow, G. E., et al. (1998). Site of opioid action in the human brain: mu and
kappa agonists’ subjective and cerebral blood ﬂow effects. Am. J. Psychiatry 155,
470–473.
Schlosburg, J. E., Whitﬁeld, T. W. Jr., Park, P. E., Crawford, E. F., George, O.,
Vendruscolo, L. F., et al. (2013). Long-term antagonism of kappa opioid receptors
prevents escalation of and increased motivation for heroin intake. J. Neurosci. 33,
19384–19392. doi: 10.1523/JNEUROSCI.1979-13.2013
Seeburg, P. H. (1993). The TINS/TiPS Lecture. The molecular biology of
mammalian glutamate receptor channels. Trends Neurosci. 16, 359–365. doi:
10.1016/0166-2236(93)90093-2
Seeburg, P. H., Burnashev, N., Kohr, G., Kuner, T., Sprengel, R., and Monyer, H.
(1995). The NMDA receptor channel: molecular design of a coincidence detector.
Recent Prog. Horm. Res. 50, 19–34.
Self, D. W., Mcclenahan, A. W., Beitner-Johnson, D., Terwilliger, R. Z., and
Nestler, E. J. (1995). Biochemical adaptations in the mesolimbic dopamine
system in response to heroin self-administration. Synapse 21, 312–318. doi:
10.1002/syn.890210405
Sepulveda, J., Oliva, P., and Contreras, E. (2004). Neurochemical changes of the
extracellular concentrations of glutamate and aspartate in the nucleus accumbens
of rats after chronic administration of morphine. Eur. J. Pharmacol. 483, 249–258.
doi: 10.1016/j.ejphar.2003.10.037
Sepulveda, M. J., Hernandez, L., Rada, P., Tucci, S., and Contreras, E. (1998).
Effect of precipitated withdrawal on extracellular glutamate and aspartate in the
nucleus accumbens of chronically morphine-treated rats: an in vivo microdialysis
study. Pharmacol. Biochem. Behav. 60, 255–262. doi: 10.1016/S0091-3057(97)
00550-9
Sesack, S. R., and Grace, A. A. (2010). Cortico-basal ganglia reward net-
work: microcircuitry. Neuropsychopharmacology 35, 27–47. doi: 10.1038/npp.
2009.93
Shabat-Simon, M., Levy, D., Amir, A., Rehavi, M., and Zangen, A. (2008). Dis-
sociation between rewarding and psychomotor effects of opiates: differential
roles for glutamate receptors within anterior and posterior portions of the ven-
tral tegmental area. J. Neurosci. 28, 8406–8416. doi: 10.1523/JNEUROSCI.1958-
08.2008
Shalev, U., Grimm, J. W., and Shaham, Y. (2002). Neurobiology of relapse to
heroin and cocaine seeking: a review. Pharmacol. Rev. 54, 1–42. doi: 10.1124/pr.
54.1.1
Shaw-Lutchman, T. Z., Barrot, M., Wallace, T., Gilden, L., Zachariou, V., Impey, S.,
et al. (2002). Regional and cellular mapping of cAMP response element-mediated
www.frontiersin.org May 2014 | Volume 5 | Article 116 | 19
Chartoff and Connery MOR–glutamate crosstalk in mesolimbic system
transcription during naltrexone-precipitated morphine withdrawal. J. Neurosci.
22, 3663–3672.
Shen, H., and Kalivas, P. W. (2013). Reduced LTP and LTD in prefrontal cor-
tex synapses in the nucleus accumbens after heroin self-administration. Int. J.
Neuropsychopharmacol. 16, 1165–1167. doi: 10.1017/S1461145712001071
Shen, H., Moussawi, K., Zhou, W., Toda, S., and Kalivas, P. W. (2011). Heroin
relapse requires long-term potentiation-like plasticity mediated by NMDA2b-
containing receptors. Proc. Natl. Acad. Sci. U.S.A. 108, 19407–19412. doi:
10.1073/pnas.1112052108
Shi, J., Li, S. X., Zhang, X. L., Wang, X., Le Foll, B., Zhang, X. Y., et al. (2009).
Time-dependent neuroendocrine alterations and drug craving during the ﬁrst
month of abstinence in heroin addicts. Am. J. Drug Alcohol Abuse 35, 267–272.
doi: 10.1080/00952990902933878
Sigmon, S. C., Dunn, K. E., Saulsgiver, K., Patrick, M. E., Badger, G. J., Heil, S.
H., et al. (2013). A randomized, double-blind evaluation of buprenorphine taper
duration in primary prescription opioid abusers. JAMAPsychiatry 70, 1347–1354.
doi: 10.1001/jamapsychiatry.2013.2216
Snyder, G. L., Galdi, S., Fienberg, A. A., Allen, P., Nairn, A. C., and Green-
gard, P. (2003). Regulation of AMPA receptor dephosphorylation by glutamate
receptor agonists. Neuropharmacology 45, 703–713. doi: 10.1016/S0028-3908(03)
00319-8
Sommer, B., Kohler, M., Sprengel, R., and Seeburg, P. H. (1991). RNA editing in
brain controls a determinant of ion ﬂow in glutamate-gated channels. Cell 67,
11–19. doi: 10.1016/0092-8674(91)90568-J
Song, I., and Huganir, R. L. (2002). Regulation of AMPA receptors during
synaptic plasticity. Trends Neurosci. 25, 578–588. doi: 10.1016/S0166-2236(02)
02270-1
Spijker, S., Houtzager, S. W., De Gunst, M. C., De Boer, W. P., Schoffelmeer, A.
N., and Smit, A. B. (2004). Morphine exposure and abstinence deﬁne speciﬁc
stages of gene expression in the rat nucleus accumbens. FASEB J. 18, 848–850.
doi: 10.1096/fj.03-0612fje
Stewart, J., De Wit, H., and Eikelboom, R. (1984). Role of unconditioned and
conditioned drug effects in the self-administration of opiates and stimulants.
Psychol. Rev. 91, 251–268. doi: 10.1037/0033-295X.91.2.251
Stinus, L., Le Moal, M., and Koob, G. F. (1990). Nucleus accumbens and amygdala
are possible substrates for the aversive stimulus effects of opiate withdrawal.
Neuroscience 37, 767–773. doi: 10.1016/0306-4522(90)90106-E
Straub, C., and Tomita, S. (2012). The regulation of glutamate receptor trafﬁcking
and function by TARPs and other transmembrane auxiliary subunits. Curr. Opin.
Neurobiol. 22, 488–495. doi: 10.1016/j.conb.2011.09.005
Surmeier, D. J., Ding, J., Day, M., Wang, Z., and Shen, W. (2007).
D1 and D2 dopamine-receptor modulation of striatal glutamatergic signal-
ing in striatal medium spiny neurons. Trends Neurosci. 30, 228–235. doi:
10.1016/j.tins.2007.03.008
Suto, N., Wise, R. A., and Vezina, P. (2011). Dorsal as well as ventral striatal lesions
affect levels of intravenous cocaine and morphine self-administration in rats.
Neurosci. Lett. 493, 29–32. doi: 10.1016/j.neulet.2011.02.011
Svingos, A. L., Garzon, M., Colago, E. E., and Pickel, V. M. (2001). Mu-opioid
receptors in the ventral tegmental area are targeted to presynaptically and
directly modulate mesocortical projection neurons. Synapse 41, 221–229. doi:
10.1002/syn.1079
Swanson, L. W. (1982). The projections of the ventral tegmental area and adja-
cent regions: a combined ﬂuorescent retrograde tracer and immunoﬂuorescence
study in the rat. Brain Res. Bull. 9, 321–353. doi: 10.1016/0361-9230(82)
90145-9
Takahashi, T., Svoboda, K., and Malinow, R. (2003). Experience strengthening
transmission by driving AMPA receptors into synapses. Science 299, 1585–1588.
doi: 10.1126/science.1079886
Tang, Y. P., Shimizu, E., Dube, G. R., Rampon, C., Kerchner, G. A., Zhuo, M.,
et al. (1999). Genetic enhancement of learning and memory in mice. Nature 401,
63–69. doi: 10.1038/43432
Tenorio, G., Connor, S. A., Guevremont, D., Abraham, W. C., Williams, J., O’Dell,
T. J., et al. (2010). ‘Silent’ priming of translation-dependent LTP by ss-adrenergic
receptors involves phosphorylation and recruitment of AMPA receptors. Learn.
Mem. 17, 627–638. doi: 10.1101/lm.1974510
Tepper, J. M., Martin, L. P., and Anderson, D. R. (1995). GABAA receptor-mediated
inhibition of rat substantia nigra dopaminergic neurons by pars reticulata
projection neurons. J. Neurosci. 15, 3092–3103.
Terwilliger, R. Z., Beitner-Johnson, D., Sevarino, K. A., Crain, S. M., and Nestler, E.
J. (1991). A general role for adaptations in G-proteins and the cyclic AMP system
in mediating the chronic actions of morphine and cocaine on neuronal function.
Brain Res. 548, 100–110. doi: 10.1016/0006-8993(91)91111-D
The National Center on Addiction and Substance Abuse, Columbia University.
(2011). Adolescent Substance Use: America’s #1 Public Health Problem. New York:
Columbia University.
Todtenkopf, M. S., Parsegian, A., Naydenov, A., Neve, R. L., Konradi, C.,
and Carlezon, W. A. Jr. (2006). Brain reward regulated by AMPA receptor
subunits in nucleus accumbens shell. J. Neurosci. 26, 11665–11669. doi:
10.1523/JNEUROSCI.3070-06.2006
Tokuyama, S., Wakabayashi, H., and Ho, I. K. (1996). Direct evidence for a role of
glutamate in the expressionof the opioidwithdrawal syndrome. Eur. J. Pharmacol.
295, 123–129. doi: 10.1016/0014-2999(95)00645-1
Trujillo, K. A. (2002). The neurobiology of opiate tolerance, dependence and sensiti-
zation: mechanisms of NMDA receptor-dependent synaptic plasticity. Neurotox.
Res. 4, 373–391. doi: 10.1080/10298420290023954
Trujillo, K. A., and Akil, H. (1991). Inhibition of morphine tolerance and depen-
dence by the NMDA receptor antagonist MK-801. Science 251, 85–87. doi:
10.1126/science.1824728
Turrigiano, G. G. (2008). The self-tuning neuron: synaptic scaling of excitatory
synapses. Cell 135, 422–435. doi: 10.1016/j.cell.2008.10.008
Ungless, M. A., Whistler, J. L., Malenka, R. C., and Bonci, A. (2001). Single cocaine
exposure in vivo induces long-term potentiation in dopamine neurons. Nature
411, 583–587. doi: 10.1038/35079077
Vaccarino, F. J., Bloom, F. E., and Koob, G. F. (1985). Blockade of nucleus
accumbens opiate receptors attenuates intravenous heroin reward in the rat.
Psychopharmacology (Berl.) 86, 37–42. doi: 10.1007/BF00431681
Van Vliet, B. J., De Vries, T. J., Wardeh, G., Mulder, A. H., and Schoffelmeer, A. N.
(1991). mu-Opioid receptor-regulated adenylate cyclase activity in primary cul-
tures of rat striatal neurons upon chronic morphine exposure. Eur. J. Pharmacol.
208, 105–111. doi: 10.1016/0922-4106(91)90060-U
Vekovischeva, O. Y., Zamanillo, D., Echenko, O., Seppala, T., Uusi-Oukari, M.,
Honkanen, A., et al. (2001). Morphine-induced dependence and sensitization
are altered in mice deﬁcient in AMPA-type glutamate receptor-A subunits. J.
Neurosci. 21, 4451–4459.
Volman, S. F., Lammel, S., Margolis, E. B., Kim, Y., Richard, J. M., Roitman, M.
F., et al. (2013). New insights into the speciﬁcity and plasticity of reward and
aversion encoding in the mesolimbic system. J. Neurosci. 33, 17569–17576. doi:
10.1523/JNEUROSCI.3250-13.2013
Waldhoer, M., Bartlett, S. E., and Whistler, J. L. (2004). Opioid receptors. Annu. Rev.
Biochem. 73, 953–990. doi: 10.1146/annurev.biochem.73.011303.073940
Weiner, D. M., Levey, A. I., Sunahara, R. K., Niznik, H. B., O’Dowd, B. F., Seeman, P.,
et al. (1991). D1 and D2 dopamine receptor mRNA in rat brain. Proc. Natl. Acad.
Sci. U.S.A. 88, 1859–1863. doi: 10.1073/pnas.88.5.1859
Weinshenker, D., and Schroeder, J. P. (2007). There and back again: a tale of nore-
pinephrine and drug addiction. Neuropsychopharmacology 32, 1433–1451. doi:
10.1038/sj.npp.1301263
Weiss, R. D., Potter, J. S., Fiellin, D. A., Byrne, M., Connery, H. S., Dick-
inson, W., et al. (2011). Adjunctive counseling during brief and extended
buprenorphine-naloxone treatment for prescription opioid dependence: a 2-
phase randomized controlled trial. Arch. Gen. Psychiatry 68, 1238–1246. doi:
10.1001/archgenpsychiatry.2011.121
Wenthold, R. J., Petralia, R. S., Blahos, J., Ii., and Niedzielski, A. S. (1996). Evidence
for multiple AMPA receptor complexes in hippocampal CA1/CA2 neurons. J.
Neurosci. 16, 1982–1989.
Wheeler, R. A., and Carelli, R. M. (2009). Dissecting motivational circuitry to
understand substance abuse. Neuropharmacology 56(Suppl. 1), 149–159. doi:
10.1016/j.neuropharm.2008.06.028
Wikler, A. (1973). Dynamics of drug dependence. Implications of a condition-
ing theory for research and treatment. Arch. Gen. Psychiatry 28, 611–616. doi:
10.1001/archpsyc.1973.01750350005001
Williams, J. T., Christie, M. J., and Manzoni, O. (2001). Cellular and synaptic
adaptations mediating opioid dependence. Physiol. Rev. 81, 299–343.
Williams, J. T., Ingram, S. L., Henderson, G., Chavkin, C., Von Zastrow, M.,
Schulz, S., et al. (2013). Regulation of mu-opioid receptors: desensitization,
phosphorylation, internalization, and tolerance. Pharmacol. Rev. 65, 223–254.
doi: 10.1124/pr.112.005942
Frontiers in Pharmacology | Neuropharmacology May 2014 | Volume 5 | Article 116 | 20
Chartoff and Connery MOR–glutamate crosstalk in mesolimbic system
Wilson, C. J., and Groves, P. M. (1980). Fine structure and synaptic connections
of the common spiny neuron of the rat neostriatum: a study employing intra-
cellular inject of horseradish peroxidase. J. Comp. Neurol. 194, 599–615. doi:
10.1002/cne.901940308
Wise, R. A. (1989). Opiate reward: sites and substrates. Neurosci. Biobehav. Rev. 13,
129–133. doi: 10.1016/S0149-7634(89)80021-1
Wise, R. A. (2004). Dopamine, learning and motivation. Nat. Rev. Neurosci. 5,
483–494. doi: 10.1038/nrn1406
Wolf, M. E. (2010). Regulation of AMPA receptor trafﬁcking in the nucleus
accumbens by dopamine and cocaine. Neurotox. Res. 18, 393–409. doi:
10.1007/s12640-010-9176-0
Wolf, M. E., Mangiavacchi, S., and Sun, X. (2003). Mechanisms by which dopamine
receptors may inﬂuence synaptic plasticity. Ann. N. Y. Acad. Sci. 1003, 241–249.
doi: 10.1196/annals.1300.015
Wolf, M. E., Sun, X., Mangiavacchi, S., and Chao, S. Z. (2004). Psychomotor stim-
ulants and neuronal plasticity. Neuropharmacology 47(Suppl. 1), 61–79. doi:
10.1016/j.neuropharm.2004.07.006
Woody, G. E., Poole, S. A., Subramaniam, G., Dugosh, K., Bogenschutz, M.,
Abbott, P., et al. (2008). Extended vs short-term buprenorphine-naloxone for
treatment of opioid-addicted youth: a randomized trial. JAMA 300, 2003–2011.
doi: 10.1001/jama.2008.574
Xi, Z. X., and Stein, E. A. (2002). Blockade of ionotropic glutamatergic trans-
mission in the ventral tegmental area reduces heroin reinforcement in rat.
Psychopharmacology (Berl.) 164, 144–150. doi: 10.1007/s00213-002-1190-3
Yuferov,V., Fussell, D., Laforge, K. S., Nielsen, D.A., Gordon,D.,Ho,A., et al. (2004).
Redeﬁnition of the human kappa opioid receptor gene (OPRK1) structure and
association of haplotypes with opiate addiction. Pharmacogenetics 14, 793–804.
doi: 10.1097/00008571-200412000-00002
Zahm, D. S., and Brog, J. S. (1992). On the signiﬁcance of subterritories in the
“accumbens” part of the rat ventral striatum. Neuroscience 50, 751–767. doi:
10.1016/0306-4522(92)90202-D
Zahm,D. S., andHeimer, L. (1990). Two transpallidal pathways originating in the rat
nucleus accumbens. J. Comp. Neurol. 302, 437–446. doi: 10.1002/cne.903020302
Zito, K. A., Vickers, G., and Roberts, D. C. (1985). Disruption of cocaine and
heroin self-administration followingkainic acid lesions of thenucleus accumbens.
Pharmacol. Biochem. Behav. 23, 1029–1036. doi: 10.1016/0091-3057(85)90110-8
Zullino,D. F., Krenz, S., Zimmerman,G.,Miozzari,A., Rajeswaran, R., Kolly, S., et al.
(2004). Topiramate in opiate withdrawal – comparison with clonidine and with
carbamazepine/mianserin. Subst. Abus. 25, 27–33. doi: 10.1300/J465v25n04_04
Conflict of Interest Statement:The authors declare that the researchwas conducted
in the absence of any commercial or ﬁnancial relationships that could be construed
as a potential conﬂict of interest.
Received: 26 February 2014; accepted: 30 April 2014; published online: 27 May 2014.
Citation: Chartoff EH and Connery HS (2014) It’s MORe exciting than mu: crosstalk
between mu opioid receptors and glutamatergic transmission in the mesolimbic
dopamine system. Front. Pharmacol. 5:116. doi: 10.3389/fphar.2014.00116
This article was submitted to Neuropharmacology, a section of the journal Frontiers in
Pharmacology.
Copyright © 2014 Chartoff and Connery. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use, dis-
tribution or reproduction in other forums is permitted, provided the original author(s)
or licensor are credited and that the original publication in this journal is cited, in
accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
www.frontiersin.org May 2014 | Volume 5 | Article 116 | 21
